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Abstract 
Bile salt hydrolase (BSH) is an intestinal bacterial enzyme that catalyzes deconjugation of 
conjugated bile acids, an essential gateway reaction in the metabolism of bile acids.  Therefore, 
BSH is a key mechanism through which the microbiota modulates host lipid metabolism and 
energy harvest.  Recent studies have shown that BSH is a promising microbiome target for 
developing novel alternatives to antibiotic growth promoters (AGPs) for animal industry and 
new measures to control obesity in humans.  However, research on BSH is still in its infancy in 
terms of both basic science and translational innovation.  In this dissertation study, 
multidisciplinary approaches in conjunction with two animal model systems (rat and chicken) 
were used to examine the impact of BSH on host physiology, to understand the BSH structure-
function relationship, and to evaluate in vivo efficacy of three identified BSH inhibitors with 
potential as novel alternatives to AGPs.  Large quantities of recombinant BSH were purified and 
encapsulated using a novel encapsulation system.  Oral administration of rats with the 
encapsulated BSH did not significantly affect host growth performance, lipid metabolism, and 
energy harvest although intestinal bile profile was significantly changed in response to BSH 
treatment.  The crystal structure of the BSH from Lactobacillus salivarius NRRL B-30514 was 
elucidated.  Comparative structural analysis identified the residues and domains that are critical 
for catalysis and substrate specificity of BSH, which was subsequently validated by site-directed 
mutagenesis as well as comparative BSH activity examination.  The in vivo efficacies of three 
BSH inhibitors caffeic acid phenethylester, riboflavin, and carnosic acid were evaluated using 
chicken model.  Dietary supplementation of the BSH inhibitors in broilers (25 mg/kg body 
weight/day) enhanced body weight gain/feed efficiency, and significantly changed host bile acid 
and transcriptome profiles at both local and systemic levels, which provided physiological, 
vii 
 
metabolomics, and molecular evidence demonstrating in vivo efficacies of the tested BSH 
inhibitors. 
Keywords: Bile salt hydrolase; lipid metabolism; structure; BSH inhibitors; non-antibiotic feed 
additive  
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Introduction 
Overweight and obesity are worldwide challenges.  The latest data provided by the World Health 
Organization (WHO) showed that around 39% of adults aged 18 and over were overweight and 
13% were obese in 2014 all over the world (WHO, 2017).  Although factors, such as genetic 
background and diet, contribute significantly to the prevalence of obesity, recent research has 
linked obesity development to the composition and function of gut microbiota (Clarke et al., 
2012; Everard et al., 2013; Turnbaugh et al., 2009a).  Therefore, manipulation of gut microbiota 
might be a promising strategy to control obesity (Ley et al., 2005; Turnbaugh et al., 2009b).  
However, key microorganisms as well as their derived factors that affect host energy harvest, 
remain to be elucidated (Boulangé et al., 2016; Hullar et al., 2012; John et al., 2016; Lin, 2011). 
 
Interestingly, despite recent extensive efforts to solve the overweight and obesity problems in 
humans by targeting gut microbiota, the animal industry has manipulated gut microbiota of food 
animals for a long time to improve production and growth performance (Dibner et al., 2005).  
Specifically, a panel of antibiotics called antibiotics growth promoters (AGPs), have been used at 
sub-therapeutic levels for more than sixty years to increase feed efficiency, energy harvest, and 
body weight gain of farm animals (Moore et al., 1946).  It has been widely recognized that the 
growth-promoting effect of AGPs is primarily mediated through altered microbiota in the animal 
intestine.  With the aid of recent 16S rDNA-based, culture-independent technologies, significant 
progresses in understanding how AGPs reshape intestinal microbial population have been made.  
Specifically, recent microbiota work has shown that the growth-promoting effect of AGPs was 
highly correlated with the decreased activity of bile salt hydrolase (BSH), an intestinal enzyme 
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that is involved in lipid metabolism and produced by many commensal bacteria, such as 
lactobacillus species (Engberg et al., 2000; Lin, 2014). 
 
The BSH protein catalyzes deconjugation of conjugated bile acids, an essential gateway reaction 
for bile acid metabolism in the small intestine (Begley et al., 2006).  The bile acids have dual 
digestive and signaling roles in the host; therefore, it has been increasingly recognized that 
intestinal BSH plays an important role in host lipid metabolism and energy harvest (Begley et 
al., 2006; Joyce et al., 2014b).  In a recent study, Joyce et al. (Joyce et al., 2014a) used a 
controlled and reductionist approach to examine the impact of bacterial BSH activity on host 
physiology and metabolism, which is the first direct evidence demonstrating that manipulation of 
in situ BSH activity significantly affects host lipid metabolism, signaling functions and weight 
gain.  Recently, our preliminary rat study showed that oral administration of Zucker fatty rats 
with a purified BSH protein significantly increased respiratory exchange ratio (RER), suggesting 
reduction of host lipid digestion or absorption (Spratt et al., 2014).  This finding promoted us to 
perform a multi-disciplinary study in Chapter II by taking advantage of our well-characterized 
BSH protein in conjunction with an established rat model as well as encapsulation technology; 
the findings from the studies described in Chapter II are expected to provide more direct 
evidence showing BSH protein’s critical role in host energy harvest and lipid metabolism. 
 
To date, although a number of BSHs have been identified from different commensal bacteria, our 
understanding of the BSH structure-function relationship is still limited (Kumar et al., 2006; 
Rossocha et al., 2005).  Characterization of the residues and domains that are critical for the 
function of the BSH protein will facilitate us to discover and optimize BSH inhibitors using a 
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computational structure-based approach.  To achieve this goal, a unique BSH protein, which was 
identified and characterized in our previous study (Wang et al., 2012b), was successfully 
crystalized in this project (Chapter III).  More importantly, comparative structural analysis of the 
L. salivarius BSH identified the residues critical for catalysis and substrate specificity, which 
were further validated by site-directed mutagenesis approach in Chapter III. 
 
In light of the findings from recent functional microbiome studies, we hypothesize that dietary 
supplementation of BSH inhibitors may inhibit intestinal BSH activity, consequently promoting 
host lipid metabolism and enhancing feed efficiency and body weight gain.  Recently, we 
identified and characterized a group of promising BSH inhibitors using an effective High-
Throughput Screening system (Lin et al., 2014; Smith et al., 2014).  In particular, three novel 
BSH inhibitors—riboflavin, caffeic acid phenethyl ester (CAPE), and carnosic acid—have 
shown potential as non-antibiotic growth promoters in poultry (Lin et al., 2014; Smith et al., 
2014).  However, it is unknown if these three BSH inhibitors could exert inhibitory effect on 
BSHs in the intestine and then affect host bile profile as well as lipid metabolism.  Therefore, in 
vivo evaluation of these three promising BSH inhibitors is essential from both translational 
development and basic mechanistic research standpoints.  In Chapter IV, a pilot chicken study 
was performed to evaluate in vivo efficacy of BSH inhibitors and understand the mechanisms 
that underpin chickens physiology through analysis of bile acid profiles and host responses, 
utilizing state-of-the-art metabolomics and genomics approaches. 
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Bile acids 
Primary bile acids are de novo synthesized from cholesterol in the liver and are conjugated to 
either glycine or taurine to form conjugated bile acids (Appleby et al., 2014; Camilleri et al., 
2015; Schaap et al., 2014).  The amphipathic characteristic of conjugated bile acid helps dietary 
lipids or fat-soluble vitamins form micelles, which facilitate their metabolism by pancreatic 
enzymes prior to their absorption (de Aguiar Vallim et al., 2013).  Thus, conjugated bile acids 
are more efficient than unconjugated bile acids for emulsification and digestion of dietary lipids 
or lipid soluble nutrients (Hofmann et al., 1992; Ridlon et al., 2006).  Following synthesis, bile 
salts are stored and concentrated in the gallbladder.  Upon food consumption, chyme from partly 
digested food is expelled from stomach into the duodenum, acids and partially digested fat would 
stimulate the secretion of secretin and cholecystokinin (CCK) (Begley et al., 2005).  
Subsequently, CCK stimulates the contraction of the gallbladder and leads to the release of bile 
salts from the gallbladder into the small intestine for lipid digestion (Johnson, 1998).  In the 
animals without a gallbladder, such as horses and rats, bile salts continuously flow directly from 
the liver into the duodenum via the bile duct. 
 
After reaching the ileum, bile salts are taken up into enterocytes via efficient membrane 
transporters and further absorbed into the portal vein to get back to the liver and finally get re-
secreted into bile; this process is called enterohepatic circulation (Begley et al., 2006; Ridlon et 
al., 2006; Roberts et al., 2002; Russell, 2009; Vlahcevic et al., 1996).  In humans, 200-600 mg 
are synthesized daily which consist 5% of the total bile acid pool of about 3 g;  approximately 
400-800 mg of bile salts are subjected to microbial transformations in the intestine (Vlahcevic et 
al., 1996).  Among the various bile salts transformations, deconjugation of conjugated bile salts 
10 
  
is the gateway reaction for bile alteration and is a prerequisite for all sterol transformation (Batta 
et al., 1990; Begley et al., 2006; Kim et al., 2005b).  Notably, in addition to direct digestive role 
in the emulsification of dietary fats in the intestine, bile acids can act as signaling molecules to 
affect energy metabolism, bile acids enterohepatic circulation, host cholesterol level, and 
triglyceride and glucose homeostasis (Joyce et al., 2014b).  In particular, unconjugated bile acids 
have been shown to specifically interact with orphan nuclear hormone receptors such as 
farnesoid X receptor (FXR) and G-protein-coupled receptor TGR 5 (Evans et al., 2009; Gupta et 
al., 2001; Houten et al., 2006; Inagaki et al., 2006; Qiao et al., 2003). 
 
Bile acids signaling 
Bile acids has been recognized to be important signaling molecules by their interaction with the 
nuclear receptor FXR, membrane G-protein-coupled receptor TGR 5 and G protein coupled 
receptor S1PR2 in the gastrointestinal system (Evans et al., 2009; Gupta et al., 2001; Houten et 
al., 2006; Inagaki et al., 2006; Li et al., 2014; Qiao et al., 2003).  The signaling pathway through 
FXR is one of the most important one. 
 
FXR is expressed in the liver, intestine and adipose tissues.  In the liver, chenodeoxycholic acid 
activates FXR and consequently induce the negative nuclear receptor small heterodimer partner 
(Jayashree et al., 2014) which activates c-Jun N-terminal kinase thus inhibits the transcription of 
CYP7A1, the enzyme catalyzes the rate limiting step for bile acid synthesis (Chiang, 2017; Holt 
et al., 2003).  The FXR/SHP mechanism is more likely to be activated under the circumstance of 
high liver bile acid concentration to inhibit bile acid synthesis to prevent liver injury.  The 
mechanism of FXR anti-lipogenic action is that activation of FXR/SHP inhibits liver X receptor 
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(LXR) induced activation of SREBP1c which in turn inhibit lipogenic genes (Ma et al., 2006).  
The activation of FXR can also increase fatty acid oxidation by the induction of peroxisome 
proliferator-activated receptor alpha (PPARα) (Pineda Torra et al., 2003).  Very low density 
lipoprotein secretion is also regulated by FXR.  The activation of FXR/SHP suppresses the 
hepatocyte nuclear factor 4α (HNF4α) activity which is the master regulator of microsomal 
triglyceride transfer protein (MTP) and Apolipoprotein B (apoB) expression and this important 
for VLDL secretion (Hirokane et al., 2004). 
 
Activation of FXR can also decrease host glucose concentration by increasing glycogen 
synthesis and decreasing gluconeogenesis and glycogenolysis (Ma et al., 2006).  The key gene 
involved in these process is the fibroblast growth factor 19 (FGF19).  The activation of FXR 
promotes FGF 19 expression which directly promotes glycogen synthesis in the liver (Kir et al., 
2011).  When glucose level is high, FXR activation reduces liver pyruvate kinase (LPK) 
transcription, which leads glucose metabolites towards glycogen synthesis (Duran-Sandoval et 
al., 2005).  Besides, inducing of FGF 19 inhibits gluconeogenesis by reducing hepatic expression 
of peroxisome proliferator-activated receptor gamma coactivator alpha (PGC1α) and cyclic AMP 
response element binding protein (CREB) (Potthoff et al., 2011).  The expression of PGC1α and 
CREB positive regulate phosphoenolpyruvate carboxykinase (PEPCK) activity which increases 
gluconeogenic (Potthoff et al., 2011). 
 
In addition to nutrient metabolism, FXR also plays important role on anti-inflammatory activity 
by inhibition NF-κB transcriptional activation of liver pro-inflammatory genes (Wang et al., 
2008).  Host immunology process can be modulated by FXR as well via autophagy and cell 
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proliferation through an interaction with energy-sensitive transcriptional coregulators (Massafra 
et al., 2017; Jayashree et al., 2014). 
 
Bile Salt Hydrolase (BSH) 
The BSH protein produced by intestinal bacteria catalyzes deconjugation of conjugated bile acids 
by hydrolyzing the amide bond and producing free amino acids and unconjugated bile acids; this 
is an essential gateway reaction in the metabolism of bile acids in the small intestine (Begley et 
al., 2006).  The BSH protein belongs to the choloylglycine hydrolase (EC 3.5.1.24) family.  
Phylogenetic analysis indicated that BSH was derived from a wider Ntn_CGH-like family of 
proteins, specifically penicillin V acylase (Jones et al., 2008; Kumar et al., 2006).  BSHs from 
various sources differ in activity, substrate specificity, and optimal temperature and pH for 
enzymatic activity (Begley et al., 2006).  Molecular weight of the BSH subunit ranges from 28 
kDa to 50 kDa, and optimal pH for BSH activity is slightly acidic with range from 3.5 to 6.  
Most identified BSHs still display activity at temperatures up to 60oC.  Many identified BSHs 
have a narrow substrates spectrum and display much higher activity in hydrolyzing glycine-
conjugated bile salts than tauroconjugated bile salts (Coleman et al., 1995; Kim et al., 2004; 
Liong et al., 2005; Pavlović et al., 2012; Smet et al., 1995; Tanaka et al., 2000).  However, some 
BSHs show a preference for tauroconjugated bile salts, such as two BSHs in Lactobacillus 
jonsonii PF01 (Chae et al., 2013) and the BSHs from five lactobacilli strains (Jiang et al., 2010).  
Recently, a potent BSH protein was identified and characterized from a chicken Lactobacillus 
salivarius strain; this BSH displayed potent hydrolysis activity towards both glycoconjugated 
and tauroconjugated bile salts (Wang et al., 2012b).  It has been proposed that BSHs recognize 
conjugated bile acids on both amino acid moieties and the cholate steroid nucleus (Begley et al., 
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2006).  Not surprisingly, substrates preferences of BSH may differ under different pH, likely due 
to pH-mediated structural changes (Corzo et al., 1999). 
 
To date, the structural basis of the BSH function is still largely unknown.  Crystal structures of 
the BSHs from only three specific species, Bifidobacterium longum, Clostridium perfrigens, and 
L. salivarius have been reported (Kumar et al., 2006; Rossocha et al., 2005; Xu et al., 2016).  
The 1.90 Å crystal structure of the L. salivarius BSH was recently determined by molecular 
replacement using the starting model of C. perfringens BSH (Xu et al., 2016).  Comparative 
structural analysis of the L. salivarius BSH also identified potential residues contributing to 
catalysis and substrate specificity. Together, unlike the binding pocket in other BSH such as the 
C. perfrigens BSH that shows an open entrance with shallow bottom, a panel of unique residues 
in the L. salivarius BSH make this BSH display narrow entrance of the binding pocket and the 
increased inner capacity of the binding pocket, which may enable substrates to sit deeply in the 
pocket with different conformation and lead to the broad spectrum of specificity (Wang et al., 
2012b; Xu et al., 2016).  Previous comparative genomics and structural studies have identified 
some conserved, catalytically important residues in the active sites of BSH (Cys2, Arg 16, 
Asp19, Asn79, Asn171, and Arg224); however, this conclusion was primarily based on the 
comparison of BSH structure to penicillin V acylase (Begley et al., 2006; Kumar et al., 2006; 
Wang et al., 2012).  To date, Cys2 is the only residue that has been subjected to site-directed 
mutagenesis and validated for its essential role in BSH activity (Kumar et al., 2006).  Therefore, 
future in-depth structural analysis of the unique L. salivarius BSH (e.g. in complex with specific 
substrate) in conjunction with comprehensive amino acid substitution mutagenesis would help to 
discover residues critical in catalysis and understand why this BSH displayed potent catalytic 
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activity toward a broad spectrum of substrates including both glycoconjugated and 
tauroconjugated bile salts. 
 
BSH-producing bacteria in the intestine 
BSHs have been identified in diverse bacterial species from different sources (Summarized in 
Table 1).  Among the BSH-producing organisms, most are Gram-positive bacteria, except two 
from Gram-negative genus Bacteroides (Lambert et al., 2008; Masuda, 1981; Stellwag et al., 
1976).  Jones et al. (2008) performed a functional and comparative metagenomics analysis of 
BSH activity in the human intestinal microbiome and showed a high level of redundancy of BSH 
distribution in the human intestine ecosystem; most BSH activity was distributed in all major 
phyla within intestinal microbiota (primarily Firmicutes, followed by Bacterioidetes and 
Actinobacteria) and across two domains of life (Bacteria and Archaea in the intestine) (Jones et 
al., 2008). 
 
BSH genes are particularly abundant in lactic acid fermenting probiotics, such as lactobacilli and 
bifidobacteria, which are the species most commonly used as probiotics due to their health-
promoting activities (Reviewed by Begley et al., 2006).  As is shown in Table 1, BSH activity 
and corresponding enzymes have been identified primarily in lactic acid bacteria isolated from 
gastrointestinal tract, which include but are not limited to L. salivarius, L. acidophilus, L. 
johnsonii, L. plantarum, B. longum, B. bifidum, B. adolescentis, and B. animalis.  BSH genes are 
either located in the chromosome or in the mobile element, such as the megaplasmid identified in 
L. salivarius UCC118 (Claesson et al., 2006).  It is not unusual that multiple BSH homologs, 
which are not identical, could be present in a single intestinal bacterial strain (Begley et al., 
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2006; Wang et al., 2012).  It has been speculated that BSH genes may be acquired horizontally 
among intestinal microorganisms (Begley et al., 2006).  However, there is no compelling 
evidence demonstrating horizontal transfer of BSH genes in intestinal microorganisms.  
 
Jones et al. (2008) also have determined that active BSHs are restricted to intestinal 
microorganisms, suggesting that BSH activity plays a role in in vivo adaptation of intestinal 
microorganisms in gastrointestinal environment and in the mutualism between intestinal 
microbiota and animal host (Jones et al., 2008).  Physiological advantages of BSH for bacterial 
producers themselves are still not well understood.  One popular opinion is that BSH activity 
contributes to the resistance of commensal bacteria towards bile salts, a natural antimicrobial 
presents in the intestine (Begley et al., 2006).  For example, it has been demonstrated that BSH 
activity plays an important role in the bile resistance and intestinal colonization of Listeria 
innocua in a mice model (Jones et al., 2008).  However, the unconjugated bile salts resulting 
from BSH hydrolysis could still display antimicrobial activity; thus, there are contradictory 
findings about the contribution of BSH activity to bile tolerance in intestinal probiotic bacteria 
(Begley et al., 2006).  At present, there is no convincing in vivo evidence demonstrating that 
BSH protein contributes to bile resistance in probiotic bacteria, such as lactobacilli.  Fang et al. 
(2009) demonstrated that the production of BSH does not determine the bile resistance level in L. 
salivarius, the dominant Lactobacillus species present in animal intestine (Fang et al., 2009).  In 
addition to this popular hypothesis, there are some other opinions about the roles of BSH in 
bacterial physiology based on some evidence in certain commensal bacteria.  For example, it has 
been proposed that hydrolysis of conjugated bile acids by BSH can provide cellular carbon, 
nitrogen, and sulfur, as well as energy source for some bacteria species (Ridlon et al., 2006; 
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Tanaka et al., 2000; Vlahcevic et al., 1996).  BSH may also trigger the influx of cholesterol or 
bile into bacterial cells and increase membrane electrochemical characteristics, which may 
facilitate some microorganisms to inhabit the gastrointestinal epithelium in the host via immune 
evasion (Jones et al., 2008; Mukherji et al., 2015). 
 
The impact of bacterial BSH activity on host physiology 
Despite the lack of understanding of the benefits of BSH for BSH-producing bacteria, it has been 
recognized that intestinal BSH plays an important role in host lipid metabolism, dietary energy 
harvest and body weight gain, because BSH catalyzes the gateway reaction in the metabolism of 
bile acids in the intestine (Begley et al., 2006; Jones et al., 2008; Joyce et al., 2014b).  To date, 
functional research on the relationship between bacterial BSH and host physiology and health 
has been primarily focused on human probiotics using laboratory animal model systems.  There 
are very limited efforts to determine the impact of intestinal bacterial BSH activity on growth 
and health in food animals (Du Toit et al., 1998; Feighner et al., 1988; Guban et al., 2006; 
Knarreborg et al., 2004; Lin, 2011; Lin et al., 2014).  The following paragraphs summarize the 
findings from laboratory animal studies and human trials, which would shed light on food animal 
health research in the future. 
 
Host lipid metabolism, cholesterol, and body weight 
Obesity associated diseases are increasing as children and adults are increasingly becoming 
overweight and obese (Kahn et al., 2006; Van Gaal et al., 2006).  Recent studies have indicated 
that intestinal microbiota are implicated in obesity in humans (Tremaroli et al., 2012); however, 
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the key microbial functions influencing host energy harvest remain to be clearly elucidated.  The 
BSH protein has been increasingly recognized as a critical intestinal microbiome target for 
developing an intervention strategy to control obesity. 
 
Given that the bile acids have dual digestive and signaling roles in the host, intestinal BSH plays 
an important role in host metabolism and energy harvest; BSH activity has a significant impact 
on host physiology by disturbing conjugated bile acids-mediated fat metabolism and endocrine 
functions (Begley et al., 2006; Jones et al., 2014; Joyce et al., 2014b; Patel et al., 2010).  Recent 
probiotics studies have already shown that oral administration of BSH-producing lactobacilli 
could affect lipid metabolism, consequently reducing body weight and/or cholesterol level in 
humans (Jones et al., 2013), rats (Kumar et al., 2011; Pato et al., 2004), mice (Miyoshi et al., 
2014; Park et al., 2013; Park et al., 2014), and pigs (De Smet et al., 1998). 
 
Molecular and cellular studies also have provided insights into the underlying mechanisms of the 
effect of BSHs on host lipid metabolism and energy harvest.  Clearly, unconjugated bile acids, 
directly resulting from BSH activity, are less effective than conjugated bile acids in the 
emulsification of dietary fat, and consequently affect lipid absorption and metabolism.  However, 
unconjugated bile acids could exert more profound impacts on host energy harvest both locally 
and systemically.  Farnesoid X receptor (FXR), which is preferentially stimulated by 
unconjugated bile acids, can not only regulate lipogenesis and triglyceride synthesis (Li et al., 
2013; Watanabe et al., 2004), but also regulates glucose homeostasis by increasing glycogen 
synthesis (Caron et al., 2013; Zhang et al., 2006) or decreasing glycolysis (Caron et al., 2013). 
Using a pig model, Pereira-Fantini et al. (2014) examined the impact of BSH-mediated bile acid 
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dysmetabolism on FXR signaling pathways and clinical outcomes, and showed that alterations in 
bile acid composition may have contributed to the observed disturbance in FXR-mediated 
signaling pathways (Pereira-Fantini et al., 2014). 
 
Notably, obesity development is a complex physiological issue.  The BSH-mediated bile salt 
metabolism is only one of several potential mechanisms by which microbiota affect host energy 
harvest and weight gain (Walker et al., 2013).  The studies described above only provide indirect 
evidence supporting the role of BSH-producing probiotics or BSH-mediated bile metabolism in 
host lipid metabolism and energy harvest.  Direct and controlled approaches are required in order 
to obtain complete understanding of BSH-mediated regulation of host weight gain and lipid 
metabolism. 
 
Recently, using a controlled system in conjunction with a mouse model, Joyce et al. (2014a) 
obtained the first direct evidence demonstrating that manipulation of in situ BSH activity alone 
significantly influenced lipid metabolism, signaling functions, and weight gain (Joyce et al., 
2014a).  Briefly, two well characterized L. salivarius BSHs were cloned into an E. coli host 
strain (MG1655).  The recombinant E. coli constructs could effectively colonize the 
gastrointestinal tract of mice with expression of high level of BSH activity.  Colonization of 
germ-free mice with such BSH-producing E. coli strain elevated intestinal BSH activity and 
resulted in local bile acids deconjugation with concomitant reduced levels in body weight and 
cholesterol, alternations in lipid metabolism, signaling functions, local and systemic 
transcriptome profiles in the pathways governing lipid metabolism (Joyce et al., 2014a).  
Notably, in conventionally raised mice, enhanced in situ BSH activity also caused local bile acid 
19 
  
deconjugation, reduced mouse weight gain, lowered serum cholesterol level, and reduced liver 
triglyceride level, which further demonstrates that BSH is a key mechanism through which the 
microbiota modulates host lipid metabolism and dietary energy harvest (Joyce et al., 2014a).  In 
addition to its ability to alter local (gastrointestinal) functions, BSH activity could systemically 
affect host physiology such that the BSH activity-mediated bile acids can interact with 
transporters (e.g. Abcg5/8) and regulators (e.g. FXR regulon, Fiaf) which lead to change in body 
mass (Joyce et al., 2014a). 
 
Other physiological processes 
The BSH-mediated unconjugated bile acids also affect immune homeostasis because of their 
ability to modulate a panel of effectors in the intestine, such as inducible NO synthase (iNOS) 
(Inagaki et al., 2006), the antimicrobial peptide RegIIIγ produced by intestinal paneth cells   
(Joyce et al., 2014a), and dendritic cell differentiation (Ichikawa et al., 2012; Joyce et al., 
2014b).  In addition to the pathway via intestinal FXR, unconjugated bile acids also affect 
TGR5-mediated adipose tissue development and weight loss (Svensson et al., 2013; Watanabe et 
al., 2006).  Interestingly, Joyce et al. (2014a) also observed that enhanced in situ BSH activity 
reversed the expression pattern of genes responsible for regulating circadian rhythm (e.g., Dbp) 
and other genes central to circadian clock (Joyce et al., 2014a).  Finally, unconjugated bile acids 
can also alter intestinal microbiota, and consequently may exert more complex impacts on the 
host (Inagaki et al., 2006; Islam et al., 2011).   
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Potential adverse effects due to high-level BSH activity in the intestine 
High-level BSH activity would result in a large proportion of unconjugated bile acids, which can 
lead to malabsorption of lipids and may cause steatorrhea in the host (Kim et al., 2005b).  Recent 
research also indicates that deconjugation of bile salts by BSH-producing lactobacilli is an 
important factor leading to short bowel syndrome due to abnormal lipid metabolism and a 
disrupted bile acid profile (Bongaerts et al., 2000; Choi et al., 2014). 
 
BSH mediated deconjugation of bile salts can increase bile recovery from passive absorption 
across the colonic epithelium by making bile salts more hydrophobic, which may also cause 
some adverse effects.  For example, a high concentration of secondary bile acids in the blood and 
feces, produced by a multistep 7α-dehydroxylation reaction from unconjugated bile acids, are 
proposed to be related to the pathogenesis of cholesterol gallstone diseases as well as colon 
cancer (Färkkilä et al., 1990; Marteau et al., 1993; McGarr et al., 2005; Ou et al., 2013; van 
Faassen et al., 1987; Venneman et al., 2010).  Secondary bile acids may increase the risk of 
cancer by increasing oxidative stress and associated  DNA damage (Bernstein et al., 2005; 
Cooke et al., 2003).  The sulfonic acid moiety in unconjugated bile acids could be reduced and 
dissimilated to hydrogen sulfide, which is highly toxic and can increase colon cell turnover 
(Christl et al., 1996; Corzo et al., 1999; Laue et al., 2001; Lie et al., 1999; Ridlon et al., 2006).  
Hydrogen sulfide is a potent inhibitor of colonic butyrate metabolism, which is a key nutrient 
and a regulator of cell turnover (Christl et al., 1996; Van Eldere et al., 1996).  Hydrogen sulfide 
can also reduce apoptosis in colon cancer cells by preventing the function of the chemo-
preventative agent β-phenylethyl isothiocyanate (PEITC) (Rose et al., 2005). 
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Target BSH for enhanced animal production and health 
In contrast to the significant progress on BSH research for human health described above, little 
information exists concerning BSH and BSH-producing bacteria in food animals.  Some early 
studies evaluated direct usage of bile salts as a feed additive to improve feed efficiency due to 
the well-recognized role of bile salts in fat digestion (Kussaibati et al., 1982; Reinhart et al., 
1988).  In chickens, supplementation of bile salts in the diet increased the absorption of fatty 
acids, but had no influence on chickens with fat-free diet (Kussaibati et al., 1982).  Presence of 
bile salts in the diet also increased fat digestibility in swine after the weaning period (Reinhart et 
al., 1988).  Although the findings from these studies are encouraging, bile salts have not been 
adopted by the feed industry as feed additives to improve growth performance of food animals, 
likely due to the issues of cost, availability, and complex biotransformation of bile salts in the 
gastrointestinal tract. 
 
AGPs are defined as a group of antibiotics used in feed at sub-therapeutic level to improve 
average daily weight gain and feed efficiency in food animals.  This husbandry technique has 
been practiced since the 1950s.  However, use of AGPs has been associated with the emergence 
of antibiotic-resistant human pathogens of animal origins.  Therefore, ending the use of AGPs is 
a worldwide trend to protect public health.  Effective alternatives to AGPs are urgently needed to 
maintain current animal production levels without threatening public health.  Recent animal 
studies on the effect of AGP usage on intestinal microbiome indicate that the enhanced feed 
efficiency and body weight gain in food animals due to AGP usage is inversely related to the 
BSH activity as well as the abundance of potent BSH-producers in the intestine (Lin, 2014).   
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As early as the 1980s, Feighner and Dashkevicz (1987) reported that use of AGP reduced 
intestinal BSH activity in poultry and proposed that inhibition of BSH activity would promote 
feed efficiency and weight gain in food animals.  In this early study, a radiochemical method was 
successfully developed to directly determine BSH activity in intestinal contents; however, the 
method used in this study was technically challenging and time consuming (Feighner et al., 
1987).  Notably, the standard BSH activity assay widely used is not feasible for examining fecal 
BSH activity because of the high levels of background caused by free amino acids in intestinal 
contents.  To date, fecal bile acid profile is an acceptable indicator for evaluating BSH activity in 
the intestinal contents.  Consistent with the finding by Feighner and Dashkevicz (1987), 
Knarreborg et al. (2004) also observed that AGP usage reduced concentration of unconjugated 
bile salts in the intestine of broilers by using reversed-phase HLPC method, which led to an 
enhanced bioavailability of α-tocopheryl (alpha-tocopherol) acetate.  In multiple pen trials, 
Guban et al. (2006) further confirmed that AGP treatment improved weight gain and fat 
digestibility in broilers, decreased population levels of L. salivarius, and significantly reduced 
BSH activity in the intestine, which was reflected by a decreased pool of deconjugated bile salts 
in ileal contents using the HPLC method.  In pigs, De Smet et al. (1998) observed that oral 
administration of L. reuteri with BSH activity influenced host lipid metabolism and decreased 
total and LDL-cholesterol concentrations.  Du Toit et al. (1998) also had a similar finding in a 
minipig feeding trials using BSH-positive probiotic mix.  However, both of these pig studies (De 
Smet et al, 1998; Du Toit et al., 1998) lack determination of intestinal BSH activity, which is 
needed to rule out potential pleotropic effects resulting from the treatment with BSH-producing 
probiotics. 
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Regarding the response of intestinal microbiota to AGPs, a key issue for us to understand the 
mode of action of AGP, culture-independent molecular approaches have been used to examine 
the effect of AGPs on intestinal microbiota in poultry and swine; to date, more than ten papers 
have been published in this filed (Lin, 2014).  Not surprisingly, long-term supplementation of 
diet with AGPs significantly affected the microbial ecology in the intestine in all reported 
studies.  However, the specific bacteria or environmental niches changes that are meaningful and 
are linked to the desired phenotype of enhanced growth performance need to be clarified.  In-
depth comparative analysis of these animal microbiome studies led to an interesting finding: in 
most chicken and swine studies, use of AGPs reduced the population of Lactobacillus species, 
the major BSH-producing bacteria in the animal intestine (Begley et al., 2006; Lin, 2014).  The 
independent findings from these food animal studies together with those from human BSH 
research summarized above are like jigsaw pieces, which seem to be scattered but are in fact 
tightly interrelated.  Therefore, it was proposed that BSH is a key mechanistic microbiome target 
for developing novel alternatives to AGPs and this hypothesis prompted us to identify and 
characterize a potent BSH protein from a chicken L. salivarius probiotic strain (Wang et al., 
2012b).  Interestingly, copper and zinc compounds displayed potent inhibitory effect on BSH 
activity in this study, which not only provides scientific evidence to understand the mode of 
action of high dietary concentrations of copper/zinc for growth promotion, but also strongly 
supports our hypothesis that BSH inhibitors may serve as promising alternatives to AGPs (Wang 
et al., 2012b).  Subsequently, by taking advantage of the unique feature of the L. salivarius BSH 
(Wang et al., 2012b), an efficient high-throughput screening system was successfully developed 
and used to discover BSH inhibitors (Smith et al., 2014).  Unlike many BSHs from other bacteria 
that have narrow substrate spectrum, the L. salivarius BSH displayed potent hydrolysis activity 
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towards both glycoconjugated and tauroconjugated bile salts.  The broad substrate specificity 
nature of this BSH makes it an ideal candidate for screening desired BSH inhibitors.  This 
hypothesis is further tested by our recent study showing the identified BSH inhibitors also 
exhibited potent inhibitory effects on a phylogenetically distant BSH from L. acidophilus (Lin et 
al., 2014). 
 
Despite the recognized AMR issues associated with antibiotic usage in food animals, animal 
industries still heavily rely on antibiotics due to the lack of practical and consistent antibiotic 
alternative approaches.  Solely limiting antibiotics without providing effective alternatives would 
compromise animal production and health.  BSH inhibitors are promising alternatives to AGPs 
for enhanced feed efficiency and growth performance.  Successful development of effective non-
antibiotic BSH inhibitor feed additives could reduce the dependence on in-feed antibiotics for 
growth promotion, consequently mitigating AMR pressure in agriculture ecosystems, which is a 
significant and timely issue impacting animal health and food safety. 
 
Other types of antibiotic-alternative products, such as probiotics, prebiotics, and organic acids, 
have drawn wide attention and have been developed and used to alter intestinal microbiota for 
improving animal health and production (Dibner et al., 2005; Lin, 2014).  However, very limited 
data is available to scientifically justify the choice of specific bacterial species or products for 
growth promotion and results are inconsistent from independent studies (Dibner et al., 2005).  
For example, although probiotics containing Lactobacillus are well recognized for their 
beneficial effects on boosting host immunity, these probiotics could have a negative impact on 
host lipid metabolism due to BSH production.  For example, in a large pen trial, (Mountzouris et 
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al., 2010; Sharifi et al., 2012) it was observed that supplementation of a 7-bacterial species 
probiotic (Protexin) to fat-rich diets significantly reduced body weight gain, fat digestibility, and 
feed conversion in broilers (Sharifi et al., 2012).  Using a different 5-bacterial species 
competitive exclusion probiotic product, Mountzouris et al. also observed similar inferior feed 
conversion efficiency and reduced fat digestibility in response to probiotic treatment in broilers 
(Mountzouris et al., 2010).  These investigators have proposed that the enrichment of the 
intestinal microflora, particularly lactobacilli, due to probiotic supplementation caused enhanced 
BSH activity in the intestine, leading to detrimental effects on lipid metabolism and growth 
performance in broilers.  Therefore, improved knowledge in the role of BSH and BSH-producing 
bacteria will help design rationally tailored probiotics that will enhance animal health and 
performance.  For example, the BSH inhibitors could also be used together with certain BSH-
producing probiotics to maximize the beneficial effects of the probiotics by mitigating their 
potential negative impact on host fat digestion.  This approach may further help animal 
production industries optimize existing probiotic and prebiotic additives for enhanced feed 
efficiency, growth performance and profitability. 
 
Conclusions and research gaps 
Antibiotics have been heavily used for animal farming to maintain animal production and health.  
However, farm usage of antibiotics is a driving force to enrich AMR genes (called the 
‘resistome’) in various niches and to promote pools of resistant pathogenic bacteria, raising food 
safety and public health concerns (Davies, 2014; Perry et al., 2014).  To effectively mitigate 
AMR in agricultural systems, a reduction in the use of antibiotics in farming is imperative.  
Thus, intensive efforts are critically needed to develop effective non-antibiotic growth promotion 
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strategies that can be practically implemented by animal producers.  Recent microbiome studies 
have provided compelling evidence that BSH is a key mechanistic microbiome target for 
developing novel alternatives to AGPs.  Development of BSH inhibitor-based non-antibiotic feed 
additives directly addresses the nutrition concern (feed efficiency/growth rate) that prevents 
animal industries from reducing antibiotic usage.  In addition to benefitting healthy animals 
under routine management, the weight-enhancing BSH inhibitors may also help sick animals 
better harvest dietary energy while combatting infectious diseases or environmental/production 
stresses. 
 
Despite the significant role of bacterial BSH activity in host lipid metabolism and energy 
harvest, research on BSH is still in its infancy.  In particular, little effort has been placed on 
characterization of BSHs and/or BSH-producing bacteria in food animals.  Several significant 
gaps remain in knowledge associated with BSH in food animal production and health.  Filling 
these gaps will not only directly benefit animal health but also provide insights and likely new 
model systems for human health research, leading to novel “One Health” measures for enhanced 
animal production, food safety, and human nutrition. 
 
• Ecology of BSHs and BSH-producing bacteria in the intestine.  To date, very limited 
BSHs were identified in the intestinal bacteria isolated from food animals (Table 1-1).  
With the aids of new generation of sequencing technologies and bioinformatics tools, 
functional and comparative metagenomics analysis of intestinal BSH in food animals is 
warranted and will provide a better picture for the diversity and function of BSH in the 
intestine. Information in conjunction with other phenotypic examinations would improve 
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our understanding on the role of BSH in the symbiotic relationship between the 
gastrointestinal microbiome and animal host.  Given that specific BSH protein(s) and 
corresponding BSH-producing bacteria may serve as biomarker for health status of 
animal host, understanding the ecology of BSHs and BSH-producing bacteria in the 
intestine would facilitate the development of diagnostics to evaluate the health status of 
animals and humans. 
 
• Comprehensive evaluation using a controlled system together with a new model system is 
still critically needed to provide new mechanistic information for the role of BSH in host 
energy harvest and weight gain.  Given the increasing awareness of the important roles of 
microbiota in intestine health, development of specifically tailored probiotics is a logical 
strategy for practical application, although this approach needs an in-depth understanding 
of the molecular, physiological, and ecological features of probiotic organisms in order to 
select and design probiotics for safe, effective administration for specific purposes.  To 
date, there are not any studies using BSH negative and BSH-overproducing probiotic 
organisms to definitively link BSH activity to the specific phenotype and their impacts on 
the host animals and native microbiome.  This is likely due to the challenge of 
manipulating BSH activity in commensal organisms for specific laboratory animal host 
and unacceptability of using generally modified organisms (GMOs) in human trials.  
While this concern has been partly addressed by recent E. coli knock-in model (Joyce et 
al., 2014a), manipulating the BSH activity of a natural intestinal commensal organism in 
an animal model would be a better approach.  Recent characterization of L. salivarius as 
a potent BSH producer (Wang et al., 2012b) provides an excellent opportunity to address 
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this issue using food animal model system because genetic tools to manipulate L. 
salivarius have been well established.  Such research efforts would enable us to better 
manage body weight by manipulating microbiota in humans and animals. 
 
• Developing alternatives to AGPs by inhibiting BSH activity in the intestine.  In addition 
to discovering more novel BSH inhibitors, comprehensive animal trials are essential to 
further evaluate and select desired BSH inhibitors.  It is likely that prolonged use of a 
particular BSH inhibitor could lead to negative physiological consequences due to 
pleotropic effects of specific inhibitor and complexity of host physiology.  For example, 
because the BSH inhibitors are expected to improve lipid metabolism, it is important to 
examine if energy harvest and weight gain is partitioned adequately and not skewed 
toward excess fat deposition, which would be undesirable for both animal producers and 
consumers.  In addition, it is also warranted to examine how inhibition of BSH activity 
affects the bile profile, as well as the gastrointestinal microbial community and all the 
implications that these changes hold for animal health and productivity. 
 
• Structural basis of BSH function.  Given the ecological diversity of BSH in intestinal 
microbiome, structure analyses of BSHs from various species are highly warranted, 
which would discover critical residues in catalysis and provide key information on the 
substrate selectivity of BSHs.  Clearly, such basic studies also will directly facilitate 
future translational research, such as using molecular docking to develop desired BSH 
inhibitors for growth promotion in food animals. 
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Table 1- 1. The BSHs identified in bacteria from various sources. 
Source Host Straina Molec
ular 
Mass 
(kDa)b 
Kmd pH 
Optimumb 
Temperat
ure 
Optimum
b 
(℃) 
Reference 
GC
A 
GDC
A 
GCD
CA 
TC
A 
TDC
A 
TCDC
A 
Human 
intestine  
           
 Bacteroides 
fragilis ATCC 
25285 
32.5 0.35  0.2  0.26  0.45  0.17  0.29  4.2-4.5 ND (Stellwag et 
al., 1976) 
 Bacteroides 
fragilis NCTC 
9343 
ND ND  ND  +  ND  ND  +  5.0-6.0 ND (Aries et al., 
1970) 
 Bacteroides 
fragilis 2536 
ND ND  +  +  +  +  +  4.5-5.0 ND (Masuda, 
1981) 
 Bacteroides 
vulgatus I-1 
ND ND  -  -  -  -  +  4.5-5.0 ND (Masuda, 
1981) 
 Bacteroides 
vulgatus VI 31 
36 -  -  -  +  +  +  5.6-6.4 ND (Kawamoto 
et al., 1989) 
 Bifidobacterium 
longum BB536 
40 1.33  1.37  1.4  0.87
5  
0.516  1.61  5.5-6.5 35-40 (Grill et al., 
1995) 
 Bifidobacterium 
longum 
SBT2928 
35 0.16  0.28  0.13  1.12  0.79  0.33  5.0-7.0 40-45 (Tanaka et 
al., 2000) 
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Table 1- 1. Continued. 
Source Host Straina Molec
ular 
Mass 
(kDa)b 
Kmd pH 
Opti
mum
b 
Temp
eratur
e 
Optim
umb 
(℃) 
Refe
renc
e 
Sour
ce 
Host 
Strain
a 
Molecular 
Mass 
(kDa)b 
Kmd pH 
Optimumb 
 Bifidobacterium 
bifidum ATCC 
11863 
35 +  +  +  +  +  +  ND ND (Kim et al., 
2004) 
 Bifidobacterium 
adolescentis 
ATCC 15705 
35 ND  ND  ND  ND  ND  ND  ND ND (Kim et al., 
2005a) 
 Clostridium 
perfringens 
ATCC 19574 
ND ND  ND  ND  ND  ND  ND  5.6-5.8 ND (Nair et al., 
1967) 
 Clostridium 
perfringens PB 
6K 
ND +  +  +  +  +  +  4.5-5.0 ND (Masuda, 
1981) 
 Clostridium 
sordellii 4709 
ND +  +  +  +  +  +  4.5-5.0 ND (Masuda, 
1981) 
 Lactobacillus 
acidophilus L1 
126c +  +  +  +  +  +  3.5-5.5 ND (Corzo et al., 
1999) 
 Lactobacillus 
acidophilus 
O16 
126c +  +  +  +  +  +  3.5-6.0 ND (Corzo et al., 
1999) 
 Lactobacillus 
acidophilus 
NCFM 
ND +  +  +  +  +  +  ND ND (McAuliffe 
et al., 2005) 
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Table 1- 1. Continued. 
Source Host Straina Molec
ular 
Mass 
(kDa)b 
Kmd pH 
Opti
mum
b 
Temp
eratur
e 
Optim
umb 
(℃) 
Refe
renc
e 
Sour
ce 
Host 
Strain
a 
Molecular 
Mass 
(kDa)b 
Kmd pH 
Optimumb 
 Lactobacillus 
sp. strain100-12 
ND ND  ND  ND  + ND  ND  ND ND (Lundeen et 
al., 1990) 
 Listeria 
monocytogenes 
ND ND  ND  ND  ND  ND  ND  ND ND (Dussurget et 
al., 2002) 
 
Murine 
intestine 
           
 Lactobacillus 
sp. strain100-
100 
42 ND  ND  ND  + ND  ND  3.8-4.5 ND (Lundeen et 
al., 1990) 
 Lactobacillus 
sp. strain100-16 
ND ND  ND  ND  + ND  ND  ND ND (Lundeen et 
al., 1990) 
 Lactobacillus 
sp. strain RI 
ND ND  ND  ND  + ND  ND  ND ND (Lundeen et 
al., 1990) 
Pig 
intestine 
           
 Lactobacillus 
acidophilus 
ATCC 43121 
126c +  +  +  +  +  +  3.5-5.5 ND (Corzo et al., 
1999) 
50 
  
Table 1- 1. Continued. 
Source Host Straina Molec
ular 
Mass 
(kDa)b 
Kmd pH 
Opti
mum
b 
Temp
eratur
e 
Optim
umb 
(℃) 
Refe
renc
e 
Sour
ce 
Host 
Strain
a 
Molecular 
Mass 
(kDa)b 
Kmd pH 
Optimumb 
 Lactobacillus 
acidophilus 
PF01 
35 - - -  +  +  +  6 40 (Oh et al., 
2008) 
 Lactobacillus 
johnsonii PF01 
36 
&37 
+  +  +  +  +  +  5.0 55 (BSH 
A) &70 
(BSH C) 
(Chae et al., 
2013) 
 Lactobacillus 
sp. strain 100-
33 
ND ND  ND  ND  + ND  ND  ND ND (Lundeen et 
al., 1990) 
 
Chicken 
intestine 
           
 Lactobacillus 
salivarius 
NRRL B-30514 
37 1.71  1.15  2.48  3.21  3.19  2.53  5.0-6.0 35-55 (Wang et al., 
2012b) 
 
Other 
           
Fermente
d milk 
Bifidobacteriu. 
animalis DN 
173010 
ND ND  ND  ND  ND  ND  ND  ND ND (Lepercq et 
al., 2004) 
Springs Brevibacullus 
sp. 
28 ND  ND  ND  ND  ND  ND  9 60 (Sridevi et 
al., 2009) 
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Table 1- 1. Continued. 
Source Host Straina Molec
ular 
Mass 
(kDa)b 
Kmd pH 
Opti
mum
b 
Temp
eratur
e 
Optim
umb 
(℃) 
Refe
renc
e 
Sour
ce 
Host 
Strain
a 
Molecular 
Mass 
(kDa)b 
Kmd pH 
Optimumb 
Fermente
d milk 
Clostridium 
perfringens 
MCV 815 
56.0 +  +  +  +  +  +  5.8-6.4 ND (Gopal-
Srivastava et 
al., 1988) 
Fermente
d finger 
millet 
Pediococcus 
pentosaceus 
KID7 
ND ND  ND  ND  ND  ND  ND  ND ND (Damodhara
n et al., 
2015) 
Fermente
d milk 
Lactobacillus 
acidophilus sp. 
ND ND  ND  ND  ND  ND  ND  ND ND (Pinto et al., 
2006) 
Parakeet  Lactobacillus 
salivarius LMG 
14476 
140 - 
142c 
+  +  +  +  +  +  5.5-7.0 ND (Bi et al., 
2013; Li et 
al., 2006) 
Raw milk Lactobacillus 
plantarum  
ND ND  ND  ND  ND  ND  ND  ND ND (Sieladie et 
al., 2011) 
Silage Lactobacillus 
plantarum 
CGMCC 8198 
35-39 ND  ND  +  -  ND  +  ND ND (Gu et al., 
2014) 
Silage Lactobacillus 
plantarum Lp09 
AND Lp45 
ND ND  ND  ND  ND  ND  ND  ND ND (Huang et 
al., 2013) 
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Table 1- 1. Continued. 
Source Host Straina Molec
ular 
Mass 
(kDa)b 
Kmd pH 
Opti
mum
b 
Temp
eratur
e 
Optim
umb 
(℃) 
Refe
renc
e 
Sour
ce 
Host 
Strain
a 
Molecular 
Mass 
(kDa)b 
Kmd pH 
Optimumb 
Kefir 
grains 
Lactobacillus 
plantarum 
BBE7 
43 ND  ND  + ND  ND  ND  ND ND (Dong et al., 
2012) 
Soil Xanthomonas 
maltophilia 
CBS 827.97 
52 1.1  ND  ND  ND  ND  ND  7.9-8.5 25-40 (Dean et al., 
2002) 
 
aATCC, American Type Culture Collection; JCM, Japanese Collection of Microorganisms; CGMCC, China General Microbiological 
Culture Collection Center; NRRL, Northern Regional Research Laboratory, the Agricultural Research Service Culture Collection. 
bND: Not Determined. 
cMolecular mass of tetramer.   
dKm, Michaelis constant in Michaelis-Menten kinetics. 
 
53 
  
Chapter II. Effects of oral administration of bile salt hydrolase on host lipid 
and energy metabolism using a rat model 
  
54 
  
Abstract 
Bile salt hydrolase (BSH), a widely distributed enzyme of the gut microbiota, has recently been 
proposed to play a critical role in host lipid metabolism and energy harvest.  Specifically, BSH 
catalyzes an essential gateway reaction in the metabolism of bile salts, leading to profound 
impact on host lipid digestion.  Extensive animal and human studies have suggested that BSH is 
a promising microbiome target for developing novel feed additives to replace antibiotic growth 
promoters and for developing new measures to control obesity in humans.  However, direct 
evidence supporting the significant role of intestinal BSH in host lipid metabolism, energy 
harvest, as well as body weight change is still very limited.  In this study, the effect of oral 
administration of encapsulated BSH on lipid and energy metabolism was determined using a rat 
model system.  Large quantities of recombinant BSH were purified from Escherichia. coli and 
encapsulated using a novel system for controlled release in the gut.  Three-week old male SD 
rats (8 rats per group) were fed with encapsulated BSH (treatment) and BSA (control) at the 
equivalent amount of 2.7 mg/kg of rat body weight daily by gavage for 9 weeks.  During each 
week, rats were placed in separate cages in a Comprehensive Lab Animal Monitoring System 
(CLAMS) to monitor individual rat respiratory exchange ratio (RER), an indicator of host energy 
harvest status.  Data were analyzed using proc mixed command in SAS v9.4 with the model 
fitted with BSH treatment, time, and animal.  The rats from two groups did not show significant 
differences (P > 0.05) in body weight, feed efficiency, weekly RER, nor concentrations of 
plasma glucose, triglycerides, and total cholesterol.  However, bile salt profile, determined by 
UPLC-MS, showed a dramatic difference in response to BSH treatment, especially in fecal 
samples. 
Keywords: Lipid metabolism, bile salt hydrolase, encapsulation, bile salt profile 
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Introduction 
Bacterial bile salt hydrolase (BSH) enzymes in the gut catalyze an essential gateway reaction in 
the metabolism of bile acid, which plays an important role in direct digestive role in the 
emulsification of dietary fats in the intestine and also serves as signaling molecules to affect 
energy metabolism, host cholesterol level, and energy homeostasis (Begley et al., 2006; Joyce et 
al., 2014b).  Although studies have provided indirect evidence to support the critical role of 
intestinal BSHs in host lipid metabolism and body weight gain, direct supporting evidence is still 
very limited.  Recently, Joyce et al. (Joyce et al., 2014a) obtained the first direct evidence 
demonstrating that manipulation of in situ BSH activity significantly affected host lipid 
metabolism, signaling functions, and weight gain by using a controlled and reductionist 
approach.  In this study, colonization of germ-free mice or conventional mice with a BSH-
producing E. coli strain elevated intestinal BSH activity and resulted in local bile acid 
deconjugation with concomitant reduced levels in body weight and cholesterol, alternations in 
lipid metabolism, signaling functions, local and systemic transcriptome profiles in the pathways 
governing lipid metabolism (Joyce et al., 2014a).  This mice work clearly identified BSH as a 
key mechanism through which the microbiota modulates host lipid metabolism and energy 
harvest.  However, this finding should be further confirmed using other controlled approaches 
with a different animal model.   
 
The hypothesis of this study is that oral administration of purified BSH would enhance intestinal 
BSH activity, consequently changing host bile profile, decreasing host lipid metabolism, energy 
harvest, and body weight gain.  To maintain maximum BSH activity in the intestine, a novel 
encapsulation approach was used to protect BSH activity through long time storage and when it 
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passes gastrointestinal tract.  To test our hypothesis, large quantities of recombinant BSH (rBSH) 
enzymes were purified and then subjected to encapsulation.  After oral administration of 
encapsulated rBSH (treatment) or BSA (control) to rats, various parameters, such as body 
weight, weekly body weight gain, feed efficiency, blood parameters (plasma glucose, 
triglycerides and total cholesterol), weekly respiratory exchange ratio (RER), and bile profile in 
fecal and plasma samples were measured. 
 
Materials and methods 
Bacterial strain, plasmid, and compound 
The E. coli JL1139 that contains a recombinant plasmid bearing a histidine-tagged BSH gene 
(Lin et al., 2014) was used for rBSH expression and purification in this study.  The key 
background information for the strain was summarized in Table 2-1.  Glycocholic acid (GCA), 
glycodeoxycholic acid (GDCA), glycochenodeoxycholic acid (GCDCA), taurocholic acid 
(TCA), taurodeoxycholic acid (TDCA), taurochenodeoxycholic acid (TCDCA) and ampicillin 
were purchased from Sigma-Aldrich (St. Louis, MO, USA). 
 
Expression and Purification of rBSH 
The procedures of protein expression and purification were as described in previous publications 
with slight modification (Lin et al., 2005; Wang et al., 2012b).  Stored E. coli JL1139 was 
streaked on Luria-Bertani (LB) agar plate with ampicillin (100 µg/ml) and cultivated overnight at 
37 ℃.  Two to three single colonies were picked from the LB agar plate and cultured in 50 mL 
LB broth with ampicillin (100 µg/ml) at 37 ℃ overnight (>16 h) in a rotary shaker.  The 
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overnight culture (10 mL) was then inoculated into 200 mL Luria-Bertani (LB) broth with 
ampicillin (100 µg/ml) and grown at 37 ℃ in a rotary shaker (300 rpm) to the mid-log phase 
(OD600nm=0.4-0.6).  One milliliter of bacterial culture was transferred to microcentrifuge tube to 
prepare “pre-induction” whole cell sample by centrifuging for 1 min at 13,000 rpm (accuSpin 
Micro 7, Fisher Scientific, Pittsburgh, PA, USA).  After removing all supernatant, the pellet was 
re-suspended in 50 µL 2 x loading buffer, pre-induction whole cell sample was stored at -20 ℃ 
freezer prior to Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) 
analysis.  Subsequently, isopropyl β-D-1-thiogalactopyranoside was added to the remaining 
culture at final concentration of 0.5 mM to induce the production of rBSH.  The culture was 
incubated at 37 ℃ for 3 hours.  At the time point of one and three hours, “post-induction” 
samples were prepared with the same procedure as “pre-induction” sample.  All of the rest 
cultures were centrifuged at 4 ℃ at 5,000 g for 20 min (Avanti J-26 XP Centrifuge, Beckman 
Counter, Indianapolis, IN, USA).  The pellet was washed with 20 mL PBS for three times.  The 
pellet was finally suspended in 20 mL of ice-cold Lysis buffer (50 mM sodium phosphate buffer, 
300 mM NaCl, 10 mM imidazole, pH 7.0) supplemented with 10 mM β-mercaptoethanol (β-
ME), 5 mM of ATP, 1 mg/ml lysozyme and 5 mM of MgCl2.  The cell solution was processed 
for sonication and the cell suspension was centrifuged at 10,000 rpm for 30 min.  After 
centrifugation, the supernatant (lysate) was used for rBSH purification as described below.  
 
The lysate was mixed with the nickel-nitrilotriacetic acid (Ni-NTA) agarose resin (Qiagen) that 
had been equilibrated with the same lysis buffer; the mixture was gently rocked for 60 min at 4 ℃.  Then, the mixture was loaded into a 15 mL polypropylene column (Qiagen) and the flow-
through was collected.  The column was then washed with 5-bed volumes of Wash buffer (50 
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mM sodium phosphate buffer, 300 mM NaCl, 20 mM imidazole, 10% glycerol, pH 7.0) 
supplemented with 5 mM β-ME, 5 mM of ATP, and 5 mM of MgCl2.  The flow-through samples 
were collected for further SDS-PAGE analysis.  Five-bed volumes of Elution buffer (50 mM 
sodium phosphate buffer, 300 mM NaCl, 300 mM imidazole, 10% glycerol, pH 7.0) 
supplemented with 5 mM β-ME were used to wash the column in order to elute the protein 
bounded with Ni-NTA.  The fractions containing rBSH, which were determined by SDS-PAGE 
as detailed below, were pooled and dialyzed against Dialysis buffer (50 mM sodium phosphate 
buffer, 10% glycerol, pH 7.0) containing 5 mM L-glutathione.  The dialyzed rBSH was collected 
and stored at -80 ℃ prior to use.  For the BSH that was used for encapsulation purpose, glycerol 
was not added in the Dialysis buffer.  The activity of purified rBSH was tested by a modified 
two-step BSH activity assay (Tanaka et al., 2000; Wang et al., 2012b) and protein concentration 
was measured using bicinchoninic acid (BCA) protein assay kit (Pierce). 
 
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 
A 5 mL 12% resolving gel was prepared by mixing 1.6 mL dd H2O, 2.0 mL 30% acrylamide, 1.3 
mL 1.5 M Tris (pH6.8), 50 µL 10% SDS, 50 µL 10% ammonium persulfate (APS) and 2 µL 
TEMED.  The mixture was loaded into hand casting plates (Bio-Rad).  The top of the gel was 
sealed with water saturated isobutanol.  After polymerization was complete (30 min), the overlay 
was poured off and the resolving gel was covered by stacking gel (1.4 mL dd H2O, 330 µL 30% 
acrylamide mix, 250 µL of 1.5 M Tris (pH8.8), 20 µL 10% SDS, 20 µL 10% APS and 2 µL 
TEMED for 2 mL stacking gel).  A clean Teflon comb was immediately inserted into the 
stacking solution until the gel is polymerized.  Five microliters of the whole cell lysate 
suspension or purified protein sample was mixed with 5 µL 2 x protein loading butter and protein 
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was degenerated by incubating in boiling water for 10 min; degenerated samples were then 
loaded in each lane and separated by SDS-PAGE at 80V for 25 min followed by 160V for 40 
minutes by electrophoresis.  The gel was stained with Coomassie blue G-250. 
 
BSH activity assay 
The two step BSH activity assay was performed based on the standard procedures described 
previously (Tanaka et al., 2000; Wang et al., 2012b).  In the first step, the reaction mix was 
composed of 178 µL reaction buffer (0.1 M sodium phosphate, pH 6.0), 10 µL of 1 µg/ µL BSH, 
10 µL of 100 mM sodium glycocholate and 2 µL of 1 M DTT.  The reaction mix was incubated 
in 37 °C water bath (or heat block) for 30 min.  Following the reaction, 50 µL reaction mix was 
mixed immediately with 50 µL of 15% trichloroacetic acid (TCA) by vortexing.  In the second 
step, the 50 µL supernatant from last step after centrifugation (12,000  g for 5 min) was mixed 
thoroughly with 950 µL ninhydrin reaction mix (5 mL of 1% w/v ninhydrin, 0.2 mL of 0.5 M 
sodium citrate buffer [pH 5.5], 1.2 mL glycerol) by vortexing.  The mixture was then incubated 
on boiling water for 14 min and the reaction was stopped by putting the reaction mix tube on ice 
for 3 min.  After cooling down, the reaction reagents was transferred into 1 mL cuvette and the 
absorbance of the reagents was measured with a Smart Spec Plus spectrophotometer (Bio-Rad) 
at 570 nm.  The absorbance at 570 nm was used to present relative BSH activity. 
 
Protein encapsulation 
The purified rBSH, as well as the control protein bovine serum album (BSA, Fisher Scientific), 
were encapsulated using an established coating system (Zhang et al., 2016).  Briefly, 650 mL of 
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dialyzed rBSH (6.15 mg/mL) was spray dried to produce micro particles with a mini spray-dryer 
(model B-290 mini spray-dryer, BÜCHI Labortechnik AG, Flawil, Switzerland) at inlet 
temperature of 105 ℃ and outlet temperature of 60 ℃ with the airflow rate of 35 m3/h and feed 
rate at 10%-15%.  Then 2.18 g of micro particles were suspended in 22 mL soybean oil in a 
beaker by stirring for 30 min.  The suspension was subsequently emulsified with 176 mL sugar-
beat pectin at O : W phase volume ratio of 1:8 using a high-speed homogenizer (12,000 rpm for 
3 min) (model Cyclone I.Q.2, The VirTis Co., Inc., Gardiner, NY, USA).  Finally, the obtained 
emulsion was vacuum freeze-dried to produce powdered sample that was stored in a -80 ℃ 
freezer prior to oral gavage for rats.  The procedures for BSA encapsulation were the same as 
rBSH encapsulation procedures.  The encapsulated particles for encapsulation measurement 
purpose was subjected to spray drying instead of freeze-drying to produce high resolution image 
through scanning electron microscopy. 
 
Scanning electron microscopy (Akbarian et al., 2016) 
LEO 1525 SEM microscope (SEM/FIB Zeiss Auriga, Oberkochen, Germany) was used for 
particle images at the Advanced Microscopy and Imaging Center at the University of Tennessee, 
Knoxville.  After encapsulation, the emulsion was spray-dried and the produced powdered 
samples were glued onto an adhesive tape mounted on the specimen stub and sputter-coated with 
a gold layer of about 5 nm in thickness as described by Zhang et al (Zhang et al., 2015a). 
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Encapsulation efficiency 
Encapsulation efficiency was determined by measuring protein amount in the aqueous phase 
after encapsulation and encapsulation efficiency were measured in duplicate.  Specifically, 40 
mL emulsions were centrifuged at 13,000 g for 2 min and the supernatant was collected for 
protein quantification using BCA assay (Pierce).  Calculation formula was as follows. 
Encapsulation	efficiency	 % = 100 ∗ Total	protein g − Free	protein(g)Total	protein	(g)  
 
Zeta potential 
The stability of encapsulation dispersion was reflected by zeta potential.  To measure Zeta 
potential, 1 mL of encapsulation emulsion was transferred to a 1.5 mL Eppendorf tube and 
centrifuged at 13,000 g for 2 min to remove free molecules in the supernatant.  After removing 
supernatant, the precipitate was dissolved in 1 mL distilled water (pH 7.0) and was further 
diluted 100-fold using distilled water (pH 7.0) for measuring zeta potential with Delsa Nano 
instrument (Beckman Coulter Inc., Fullerton, CA, USA).  Zeta potential was measured in 
triplicate. 
 
Rat experiment 
The process of rat experiment followed the University of Tennessee Institutional Animal Care 
and Use Committee protocol (IACUC # 2123).  Newly born Sprague Dawley (SD) male rats 
were kept with original mother rats for 3-week of lactation period.  Subsequently, 16 male SD 
rats at weaning were randomly allocated into two groups (eight rats per group) and each group of 
rats was randomly allocated into four rat stocks (two rats per stock).  During 9-week experiment 
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period, each rat was fed with water dissolved with encapsulated rBSH or BSA (2.7 mg/kg body 
weight) daily by gavage in the evening (at 6:00 pm) when rodents begin to eat.  Along the 
experimental process, rat body weight (BW) was determined weekly in conjunction with dorsal 
blood glucose concentration measurement using glucometer (Bayer).  Each rat was housed in one 
chamber in a comprehensive laboratory animal monitoring (CLAMS) system for two times each 
week and for each time, rat respiratory exchange ratio (RER) was constantly measured for 24 
hours.  RER is the ratio between amounts of carbon dioxide (CO2) produced and oxygen (O2) 
consumed in metabolism; the value of RER gives an indication of predominant fuel sources for 
the host.  Rat feed intake was measured during the time rats were kept in CLAMS.  All rats were 
deprived of food for 12 hour and euthanized by CO2 upon termination of the experiment.  Upon 
euthanizing, rats were dissected and 5 mL rat vena cava blood, intestine and fecal samples 
(triplicate) were collected.  Blood samples were stored in vacuum blood collection tubes at 4 °C 
immediately and centrifuged at 4,000 g for 15 min, while the upper phase of plasma was 
collected and aliquoted into Eppendorf tubes and stored in -80 °C freezer prior to use.  The 
collected tissue samples were stored in a -80 °C freezer prior to analysis. 
 
Plasma biochemical analyses 
The concentrations of plasma glucose, triglycerides, and total cholesterol were determined using 
commercial kits (Stanbio Laboratory Inc., Boerne, TX, USA) following standard protocols. 
Analyses were conducted in triplicate. 
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Bile profiles analyses  
Chicken fecal samples (about 300 µL) and plasma samples (500-800 µL) from all sixteen rats 
were packed with dry ice and shipped to Dr. Susan Joyce (APC Microbiome Institute, University 
College Cork, Ireland) for bile acid profile analysis.  The metabolomics analysis was performed 
by Ultra Performance Liquid Chromatography–Tandem Mass Spectrometry (UPLC-MS); the 
detailed procedures for bile acids extraction, characterization, and quantification were described 
in a previous publication (Joyce et al., 2014a).  The metabolomics data were subjected to 
statistical analysis as described below. 
 
Statistical analysis 
The concentrations of plasma glucose, total cholesterol and triglycerides; body weight and 
weekly blood glucose concentrations were analyzed using mixed model analysis of variance 
procedure; RER data were analyzed using mixed model analysis of variance procedure with rat 
age as repeated measure and rBSH treatment as fixed effect.  All of these analyses were 
conducted with SAS v9.4 (SAS Institute, Cary, NC, USA) and least square means were 
compared at the significance level of P-value less than 5% (0.05). 
 
Results 
Expression and purification of rBSH 
As is shown in Figure 2-1, upon induction by IPTG for 1 hr, there was a dramatic increase in the 
production of protein with the molecular size of 32 kDa on SDS-PAGE, which was consistent 
with the estimated molecular size of L. acidophilus rBSH.  High purity of the C-terminal His-
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tagged rBSH was subsequently detected in eluted fractions (lane1-8) of E. coli culture usingNi-
NTA agarose affinity chromatography.  Approximately 250 mg of rBSH were routinely purified 
from 1 liter of induced E.coli culture.  A total 7.24 g of rBSH was purified for this study.  
Detailed information about stock rBSH is presented in Table 2-2 and the purified rBSH showed 
comparable activity based on BSH two-step activity assays (data not shown). 
 
Protein recovery rate during encapsulation and encapsulation efficiency 
After the very first step of rBSH encapsulation-spray drying, the activity of enzyme powder was 
also measured by BSH activity assay and showed that the activity of spray-dried BSH powder 
was dramatically decreased (>70% reduction).  However, it was not applicable to measure 
encapsulated rBSH activity before oral gavage due to technique limitation.  The recovery rate for 
rBSH in the spray drying step was 27% (1.109 g/4 g).  The recovery rate for BSA in the spray 
drying step was 23.6% (0.3776 g/1.6 g).  Encapsulation efficiency of BSA was 25% based on 
duplicate experiments. 
 
Morphology of spray-dried encapsulated protein 
SEM images of spray-dried BSA emulsions are shown in Figure 2-2.  Particles from different 
scopes showed that most particles had consistent size and shape; most spray-dried encapsulated 
BSA were ball-shaped particles with a dimension of around 10 µm.  Since only spray-dried 
encapsulated protein can be tested with SEM microscope, spray-drying had a very low recovery 
rate and a dramatic enzyme activity loss, the morphology of encapsulated rBSH was not verified. 
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Zeta potential of reconstituted emulsions 
Zeta potential of reconstituted emulsions of BSA is reported in Table 2-3.  Zeta potential was 
measured at pH 7.0 where emulsions showed most stable emulsions based on previous 
publication (Zhang et al., 2015b).  The mean of zeta potential measurements of triplicate was 
43.6±7.27 mV. 
 
Growth performance in response rBSH treatment 
During the nine weeks of the experiment, rats showed normal growth behavior, except that one 
rat in the treatment group stopped growing at five-week-old all through it showed abnormal 
behavior.  Data from this specific rat were excluded from later analysis.  Due to the uncertainty 
of encapsulated BSH and potential low efficacy of BSH in the intestine, the treatment plan was 
changed by the end of week 6 of the experiment time.  Instead of feeding rats with encapsulated 
rBSH or BSA, rats started to be fed with freshly prepared rBSH and BSA in the treatment group 
and the control group respectively at an equivalent amount of 2.7 mg/kg relative to rat body 
weight.  Rat growth performance data (body weight, body weight gain, feed intake, and feed 
conversion ratio) did not show statistically significant difference (P > 0.05) between rBSH and 
BSA treatment group (Table 2-4). 
 
Respiratory exchange ratio 
RER is an indicator of predominant fuel sources for animals.  In this study, RER in both light 
cycle (7:00 -19:30) and dark cycle (19:30 -7:00) between encapsulated BSH and BSA treatment 
group during nine weeks of the treatment period were measured (Table 2-5).  The RER value in 
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the light cycle and dark cycle ranging from 0.9279 to 1.0019, which indicated that carbohydrate 
was the predominant fuel sources for rats when they were set in the CLAMS chambers. 
 
Biochemical analysis of plasma  
Weekly dorsal blood glucose concentration of rats tested by glucometers from rBSH and BSA 
treatment group did not show a statistical difference for nine weeks of the treatment period (P > 
0.05) (Table 2-6).  Besides, compared to BSA treatment, BSH treatment did not affect the 
concentration of glucose (P = 0.3902), triglycerides (P = 0.7813), and total cholesterol (P = 
0.6161) in rat plasma (Table 2-7). 
 
Bile salts profile alterations in rat plasma and fecal samples by rBSH  
Plasma samples and fecal samples from each rat in the two treatment groups (encapsulated rBSH 
and BSA) were processed for bile salts profile test by UPLC-MS.  Twenty-two bile acids and 
amino acids related to bile metabolism were qualified and quantified (Table 2-8).  The variation 
for some bile salts was large especially for those bile salts with low concentration; in fecal 
glyhyodeoxycholic acid (GHCA), the mean square error was 0.4605 which was almost half for 
the mean concentration of fecal GHCA in the treatment group and one third of the mean 
concentration of fecal GHCA in the control group. 
 
PCA plot of bile acids (Figure 2-3) showed that rBSH treatment did not cause well separation of 
bile acid profile from BCA control group based on PC1, PC2, and PC3 for fecal samples (Figure 
2-3A) and plasma samples (Figure 2-3B), which indicated that rBSH treatment caused bile acid 
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signature difference in neither fecal nor plasma samples.  When checking each individual bile 
acids (Table 2-8) concentration in fecal samples, rBSH treatment caused significant difference in 
most of the measured bile acids (P < 0.05), namely taurine, TCA, TLCA, TUDCA,TDCA, total 
TMCA, LCA, HCA, α-MCA, β-MCA, ω-MCA, GCA ,GCDCA, GUDCA,  GHCA, and  total 
secondary and tertiary bile acids.  While in the plasma, three of secondary bile salts had a 
significantly higher level in rBSH treated group than in the control group; the three bile salts 
were LCA (P = 0.0033), DCA (P = 0.0423) and GHCA (P = 0.0027). 
 
Discussion 
For this project, we intended to encapsulate BSH using the novel technology (Zhang et al., 2016) 
for enhanced in vivo delivery and availability of BSHs.  However, multiple steps of 
encapsulation have led to dramatic reduction in both yield and activity of rBSH.  Specifically, 
the recovery rate for rBSH in the spray-drying step was only 27% and the activity of the rBSH 
following spray-drying decreased to about 33% of freshly prepared rBSH.  In addition, during 
the encapsulation step, the method used in this project only led to about 25% encapsulation rate 
(estimated by the encapsulation efficiency of BSA).  Therefore, approximately 98% of the BSH 
activity was lost after multiple steps of encapsulation in this study, which raised a significant 
challenge for encapsulation of BSHs for the proposed rat study. 
 
Due to the challenge of dramatic reduction in the quality and activity of rBSH, an alternative 
approach to oral delivery of protein is likely a promising method.  Oral administration of 
genetically modified BSH-producing Lactobacillus will be considered.  First of all, genetic 
modification of Lactobacillus has already been established (Law et al., 1995; Van Gaal et al., 
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2006) and Lactococcus has been developed as a vehicle to deliver therapeutic agents to the 
gastrointestinal (GI) tract in the past decades (Steidler et al., 2006; Wells et al., 2008).  Bao et al. 
(Bao et al., 2013) tested the effectiveness of oral administration of Lactobacillus.  They found 
that after 24 h of oral feeding of Lactobacillus to neonatal SD rats, about 3% of the bacteria were 
retained in the GI tract and more bacteria were found in the stomach and small intestine than 
cecum and colon.  Lactobacillus as an oral delivery vehicle also showed dramatically lower 
mortality than using E. coli as an oral delivery vehicle to neonates (Bao et al., 2013).  In 
addition, preparation of sufficient Lactobacillus culture requires much less work than the 
preparation of protein.  Notably, to enhance bacterial colonization in the small intestine and 
decrease cell death under harsh conditions in the GI tract, a novel encapsulation system has been 
established in emulsion of Lactobacillus with multiple lipid-protein-pectin layers (Zhang et al., 
2016). 
 
Respiratory exchange ratio was used in this project to indicate the fuel source and energy 
expenditure of rats.  However, there was no significant difference between the rBSH and BSA 
treatment groups, primarily due to the low activity of encapsulated BSH.  This also could be due 
to lower energy requirement when the rats were staying in the CLAMS chambers.  In the 
process, it was observed that rats had lower activity when individual rats were kept in separate 
chambers than two rats kept in the regular chambers.  In a recent study (Paes et al., 2016), 
researchers looked into RER change of Wistar rats during activities with different intensities.  In 
a moderate-intensity continuous excise, the RER of Wistar rats was significantly lower than a 
high-intensity continuous excise.  Even though they used a different animal model, their results 
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implied that the RER data from this study from the CLAMS system may not represent the RER 
level when rats were in normal natural activity. 
 
In the future, other animal models, such as mouse and chicken, may be used to validate the 
physiological role of BSH.  However, the several factors need to be taken into consideration.  
First and foremost, bile profile for different animals varies.  In rats, the predominant conjugated 
bile salts are glycine conjugated bile salts, while in mouse and chicken, predominant conjugated 
bile salts are taurine conjugated bile salts.  While the proposed mechanism of BSH effects on 
host physiology is mediated through deconjugation of bile salts in the intestine, the downstream 
changes in bile profile resulting from bile decongujation can further affect host physiology 
through complex signaling pathways (Joyce et al., 2014b).  In this case, even if other factors are 
well controlled, the animals fed with the same BSH may show different physiological response 
due to differences in bile profile and substrates preference of BSH.  To address this issue, we 
may use the BSH with wide substrates spectrum such as the BSH from Lactobacillus salivarius 
NRRL B-30514 (Wang et al., 2012b).  Additionally, different animal models also have different 
characteristics of lipid metabolism (Suckling et al. (1993).  Take fatty acid synthesis process for 
example, chicken use the liver as the major tissue for fatty acid synthesis while for mouse, both 
liver and adipose tissues are used for fatty acid synthesis.  When testing plasma parameters 
(especially lipoproteins) as indicators of host lipid metabolism, the choice of a specific animal 
model is also a factor that needs to be considered (Suckling et al., 1993). 
 
In conclusion, though sufficient high-quality rBSH (7.24 g) was purified in this study and 
subsequently encapsulated for rat oral administration, solid direct evidence related to BSH 
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function towards host lipid metabolism and energy harvest was not obtained.  Dramatic fecal bile 
profile change in response to BSH treatment gave us confidence of BSH physiological roles.  
The above approaches need to be considered to get direct evidence of BSH function. 
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Table 2- 1. Key background information for the BSH produced by the recombinant E. coli 
JL1139. 
Parameters  Corresponding information 
Source organism  Lactobacillus acidophilus PF01 
DNA source  Genomic DNA 
Cloning vector  pET-21b  
Expression vector  pET-21b 
Expression host  E. coli BL-21(DE3) 
Complete amino 
acid sequence of 
the construct 
produced a 
MCTGLRFTDDQGNLYFGRNLDVGQDYGEGVIITPGNYPLPYKF
LDNTTTKKAVIGMGIVVDGYPSYFDCYNEDGLGIAGLNFPHFA
KFSDGPIDGKINLASYEIMLWVTQNFTHVSEVKEALKNVNLVN
EAINTSFAVAPLHWIISDSDEAIIVEVSKQYGMKVFDDKVGVLT
NSPDFNWHLTNLGNYTGLNPHDATAQSWNGQKVAPWGVGTG
SLGLPGDSIPADRFVKAAYLNVNYPTAKGEKANVAKFFNILKS
VAMIKGSVVNDQGKDEYTVYTACYSSGSKTYYCNFEDDFELK
TYKLDDHTMNSTSLVTYLERHHHHHH 
 
 
a The His-tag site is underlined.  
The key information of BSH was originally introduced in a previous publication(Oh et al., 
2008).  
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Table 2- 2. Summary of mass production of rBSH. 
Experiment 
stock 
Culture 
volume 
(mL) 
rBSH concentration 
(mg/mL) 
 
Purified rBSH 
volume (mL) 
rBSH amount 
(Paes et al., 
2016) 
1/7/2017 500 13.6 3.5 47.6 
  7.0 8 56 
1/9/2015 2000 15.9 13 206.7 
  5.3 33 174.9 
1/21/2015 1500 16.8 16 268.8 
  3.8 34 129.2 
2/10/2015 2500 16.0 32.5 520 
  2.4 50 120 
3/23/2015 2000 9.0 42.5 382.5 
  2.3 50 115 
3/24/2015 2000 10.4 41 426.4 
  2.5 53 132.5 
4/22/2015 3000 11.7 55 643.5 
  2.6 62 161.2 
4/23/2015 3000 11.8 57 672.6 
  1.5 82 123 
4/28/2015 3000 7.7 40 308 
  7.6 45 342 
5/7/2015 3000 9.2 45 414 
  8.9 41 364.9 
5/16/2015 3000 10.6 45 477 
  10.0 46.5 465 
5/27/2015 3000 6.8 34 231.2 
  8.6 27 232.2 
  6.8 35 239 
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Table 2- 3. Zeta potential of reconstituted emulsions at pH 7.0. 
 Temperature (℃) Zeta potential (mV) 
Mean 25 -43.6 
Standard 
Deviation 0.1 7.27 
RSD %a 0.28 16.7 
Minimum 24.9 -58.5 
 
a  RSD stands for relative standard deviation. 
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Table 2- 4. Growth performance of rats in response to rBSH and BSA treatment. 
Body weight (g/rat) 
Treatment time  
(week) 
BSA rBSH P value 
1 54.73±5.30 54.9±5.70 0.9016 
2 91.07±6.84 89.12±8.05 0.9281 
3 143±8.38 136.81±10.06 0.5895 
4 185.35±7.72 176.53±11.5 0.5217 
5 232.86±11.0 222.81±14.01 0.8450 
6 265.65±11.38 253.98±16.06 0.9485 
7 296.12±11.21 280.39±17.74 0.8224 
8 315.65±10.97 302.97±19.45 0.4704 
9 336.03±11.6 339.04±12.81 0.5931 
Body weight gain (g/rat/day) 
Treatment time  
(week) 
BSA rBSH P value 
1 5.19±0.53 5.21±0.56 0.9764 
2 6.49± 0.51 6.21± 0.97 0.8073 
3 7.06± 0.46 6.97± 1.19 0.9495 
4 7.92± 0.81 8.29± 2.20 0.8798 
5 5.47± 0.17 5.68± 0.42 0.6524 
6 4.35± 0.14 4.15± 0.15 0.3677 
7 2.79± 0.19 3.46± 0.20 0.0529 
8 2.91± 0.19 2.78± 0.20 0.6517 
Feed intake (g of feed/rat/day) 
Treatment time  
(week) 
BSA rBSH P value 
1 17.18±2.35 13.91±5.86 0.6253 
2 14.55±1.14 13.87±1.21 0.6991 
3 22.64±2.96 15.10±7.57 0.3895 
4 19.24±0.87 18.94±0.93 0.8202 
5 24.53±0.86 25.39±2.22 0.7286 
6 25.17±0.87 25.19±1.80 0.9933 
7 24.14±1.05 25.16±2.30 0.7019 
79 
  
Table 2- 4. Continued. 
Feed intake (g of feed/rat/day) 
Treatment time  
(week) 
BSA rBSH P value 
8 25.06±1.00 24.95±1.08 0.9469 
Feed Conversion Ratio (g of feed/ g of weight gain) 
Treatment time  
(week) 
BSA rBSH P value 
1 4.03±1.22 2.86±3.30 0.7524 
2 2.33±0.20 2.25±0.22 0.7844 
3 3.27±0.48 2.19±1.23 0.4418 
4 2.74±0.46 2.30±1.24 0.7497 
5 4.50±0.15 4.48±0.29 0.9566 
6 5.82±0.30 6.16±0.33 0.4649 
7 8.80±0.53 7.45±0.96 0.2661 
8 8.65±0.48 9.32±0.52 0.3875 
 
Growth performance data (body weight, body weight gain, feed intake and feed conversion ratio) 
are represented as mean of corresponding parameters with standard error. Statistical significant 
level of difference is defined by P<0.05.  
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Table 2- 5. Respiratory exchange ratio for rats in response to encapsulated rBSH and BSA 
treatment. 
Respiratory exchange ratio at Light cycle 
Treatment 
time  (week) 
BSA rBSH MSE P value 
1 0.9297 0.9320 0.006450 0.8071 
2 0.9426 0.9481 0.007441 0.6104 
3 0.9612 0.9699 0.007509 0.2659 
4 0.9491 0.9579 0.007623 0.2676 
5 0.9685 0.9810 0.01003 0.2328 
6 0.9663 0.9901 0.01556 0.1472 
7 0.9728 0.9486 0.02092 0.2670 
8 0.9764 0.9717 0.008247 0.5801 
9 0.9715 0.9600 0.01152 0.3575 
Respiratory exchange ratio at Dark cycle 
Treatment 
time  (week) 
BSA rBSH MSE P value 
1 0.9753 0.9663 0.008618 0.4689 
2 0.9919 0.9884 0.007666 0.6598 
3 1.0019 0.9955 0.003775 0.2569 
4 0.9854 0.9883 0.003676 0.5791 
5 0.9944 0.9972 0.005567 0.7242 
6 0.9873 0.9798 0.004367 0.2483 
7 0.9912 0.9853 0.005181 0.4370 
8 0.9908 0.9891 0.003125 0.7043 
9 0.9831 0.9795 0.005307 0.6432 
 
Mean of RER was expressed as least square means and mean square error [MSE].  Statistical 
significant level of difference is defined by P<0.05. 
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Table 2- 6. Weekly blood glucose concentration (mg/dL) for rats in response to 
encapsulated rBSH and BSA treatment. 
Experimental Time 
(Week) 
Control Treatment MSE P value 
1 155 141.75 10.844 0.4162 
3 119.75 131.00 8.663 0.2507 
4 129.5 116.17 10.58 0.2967 
5 133.88 124.86 10.103 0.4067 
6 122.25 130.5 8.1761 0.3466 
7 115.63 115.25 5.939 0.9514 
8 117.29 106 8.8579 0.2586 
 
Mean of weekly blood glucose concentration was expressed as least square means and mean 
square error [MSE].  Statistical significant level of difference is defined by P<0.05.  
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Table 2- 7. Summary of rats’ vena cava plasm biochemical analyses in response to 
encapsulated rBSH and BSA treatment. 
Plasma parameters 
(mg/dL) Control Treatment MSE P value 
Glucose 462.37 441.49 9.7722 0.3902 
Triglycerides 104.78 100.79 7.9383 0.7813 
Total Cholesterol 105.59 100.47 7.6389 0.6161 
 
Plasma glucose, triglycerides and total cholesterol concentrations were expressed as least square 
means and mean square error [MSE].  Statistical significant level of difference is defined by 
P<0.05. 
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Table 2- 8. Fecal bile acid (ug/g) profile analyzed by UPLC-MS. 
Bile  salts Full name of bile salts Control  Treatment MSE P value 
Taurine Taurine 120.38 148.64 9.8794 0.0515 
TCA Taurocholic acid 10.5798 6.6377 1.0495 0.0149 
TCDCA Taurochenodeoxycholic acid 6.0094 5.1918 1.8417 0.7430 
TLCA Taurolithocholic acid 1.3550 1.0168 0.1270 0.0671 
TUDCA Tauroursodeoxycholic acid 2.9235 4.4414 0.2618 0.0009 
THCA Taurohyodeoxycholic acid 4.7950 6.1966 1.8979 0.5869 
TDCA Taurodeoxycholic acid 9.2947 4.5432 1.2712 0.0153 
Total 
TMCA 
Total Tauromuricholic acid 6.8778 2.4340 0.7090 0.0005 
LCA Lithocholic acid 245.45 770.26 95.7859 0.0014 
DCA Deoxycholic acid 2260.62 2908.53 265.06 0.0894 
UDCA Ursodeoxycholic acid 3961.67 5735.64 644.03 0.0594 
CDCA Chenodeoxycholic acid 5.5065 2.6832 1.9783 0.3019 
CA Cholic acid 44.3177 61.8340 11.0836 0.2553 
HCA Hyodeoxycholic acid 13.7126 24.9600 2.2431 0.0026 
β _MCA β-Muricholic acid 903.56 3343.24 252.76 <.0001 
ω _MCA ω-Muricholic acid 1744.25 3314.10 328.48 0.0036 
α _MCA α-Muricholic acid 1458.80 2737.73 331.24 0.0129 
GCA Glycocholic acid 5.3912 28.2321 4.0795 0.0012 
GCDCA Glycochenodeoxycholic acid 1712.03 5415.42 552.84 0.0003 
GUDCA Glycoursodeoxycholic acid 339.18 854.93 113.43 0.0049 
GDCA Glydeoxycholic acid 2.6854 3.9589 0.4267 0.0435 
GHCA Glyhyodeoxycholic acid 1.6064 1.1561 0.4605 0.4740 
PBA Primary bile salts 49.8242 64.5172 10.6524 0.3177 
STBA Total secondary and tertiary 
bile salts 
6467.74 9414.43 842.73 0.0214 
 
Mean of each bile acids was expressed as least square means and mean square error [MSE].  
Statistical significant level of difference is defined by P<0.05. 
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Table 2- 9. Plasma bile acid (ug/mL) profile analyzed by UPLC-MS. 
Bile salts  Full name of bile salts Control  Treatment MSE P value 
Taurine Taurine 13.5814 17.4414 1.6963 0.1299 
TCA Taurocholic acid 3.7112 4.1470 1.0001 0.7625 
TCDCA Taurochenodeoxycholic acid 0.9345 0.9103 0.1338 0.9002 
TLCA Taurolithocholic acid 0.08604 0.1794 0.05488 0.2489 
TUDCA Tauroursodeoxycholic acid 0.4873 0.5627 0.07624 0.4958 
THCA Taurohyodeoxycholic acid 1.7714 2.2943 0.3138 0.2583 
TDCA Taurodeoxycholic acid 0.8528 1.0904 0.1637 0.3222 
Total 
TMCA 
Total Tauromuricholic acid 0.7660 1.0493 0.2001 0.3339 
LCA Lithocholic acid 0.2654 0.6737 0.08185 0.0033 
DCA Deoxycholic acid 1.8694 3.4227 0.4917 0.0423 
UDCA Ursodeoxycholic acid 7.7613 24.1660 7.5709 0.1478 
CDCA Chenodeoxycholic acid 6.1267 12.1510 2.5302 0.1144 
CA Cholic acid 47.5023 116.87 29.8691 0.1228 
HCA Hyodeoxycholic acid 0.1175 0.09284 0.02424 0.4837 
β _MCA β-Muricholic acid 5.3919 14.3672 4.5837 0.1879 
ω _MCA ω-Muricholic acid 5.6672 20.0781 7.2193 0.1799 
α _MCA α-Muricholic acid 3.7615 14.2457 5.4299 0.1937 
GCA Glycocholic acid 5.8857 13.1302 3.4670 0.1617 
GCDCA Glycochenodeoxycholic acid 947.96 1765.69 464.70 0.2338 
GUDCA Glycoursodeoxycholic acid 211.68 583.19 180.92 0.1685 
GDCA Glydeoxycholic acid 1.1492 2.4109 0.4379 0.0610 
GHCA Glyhyodeoxycholic acid 1.0377 0.1966 0.1639 0.0027 
PBA Primary bile salts 53.6289 129.02 32.1905 0.1200 
STBA Total secondary and tertiary 
bile salts 
9.8961 28.2625 7.9712 0.1255 
 
Mean of each bile acids was expressed as least square means and mean square error [MSE].  
Statistical significant level of difference is defined by P<0.05.
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Figure 2- 1. Purification of L. acidophilus BSH enzyme. 
Lane M, EZ RunTM prestained molecular mass marker; 0 hr, whole cell lysate of non-induced 
E.coli; 1 hr, whole cell lysate of E. coli induced with 0.5 mM IPTG for 1 hr; 3 hr, whole cell 
lysate of E. coli induced with 0.5 mM IPTG for 3 hr; lane 1-8, eluted fractions during protein 
purification. 
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Figure 2- 2. Morphology of spray-dried encapsulated powder with BSA. Both figures are 
for spray-dried encapsulated BSA from different scope. Scale bar equals to 10 µm. 
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Figure 2- 3. PCA plot of bile acid signatures for rBSH and BSA treated rats groups in (A) 
fecal and (B) plasma. 
  
88 
  
Chapter III. Structural and functional studies of the bile salt hydrolase from 
Lactobacillus salivarius 
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Abstract 
The bile salt hydrolase (BSH) is a gut bacterial enzyme that negatively influences host fat 
digestion and energy harvest.  Bile salt hydrolase activity functions as a gateway reaction in the 
small intestine by deconjugation of conjugated bile acids.  Extensive gut microbiota studies have 
suggested that BSH is a key mechanistic microbiome target for developing novel non-antibiotic 
feed additives to improve food animal production, and for designing new measures to control 
obesity in humans.  However, research on BSH is still in its infancy, particularly with respect to 
the structural basis of BSH function, which has hampered the development of BSH-based 
strategies for improving human and animal health.  Based on previous protein crystallization 
work of BSH from Lactobacillus salivarius NRRL B-30514 and comparative structural analysis 
of L. salivarius BSH with other published BSH structure, several residues critical for catalysis 
and substrate specificity were identified.  Replacement of the residue Cys2 with serine abolished 
the activity of the L. salivarius BSH, confirming that Cys2 plays an essential role in BSH 
catalysis.  In addition, the Tyr24, Phe65, Asn171, Gln257, Glu270 amino acids and the motif 
from 164 to 171, were verified to be important for BSH activity and/or substrates specificity 
using site-directed mutagenesis approach.  Together, based on the first crystal structure of the 
BSH from Lactobacillus species, which are the major BSH producer in the intestine.  Our 
findings also provided insights into the structural basis of BSH activity, which is important for 
future translational research by identifying compounds to modulate in situ BSH activity. 
Keywords: Bile salt hydrolase, crystal structure, critical residues  
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Introduction 
Recent studies indicated that gut microbiota affects host energy metabolism and obesity 
development (Gérard, 2016; Krznarić et al., 2012).  Thus, manipulating gut microbiota can be a 
promising way to control obesity and obesity-associated diseases.  The understanding of the 
working mechanism of antibiotic growth promoters (AGPs) also related animal energy harvest 
and growth promotion effects to intestinal microbiota (Begley et al., 2006).  Those findings 
suggested that gut bile salt hydrolase (BSH) is a key microbial target to control host lipid 
metabolism and energy harvest, thus to develop alternatives to AGPs and serve as new measures 
to control obesity in human.  The BSH catalyzes gateway reaction in bile acids metabolism in the 
small intestine and the change of bile profile will affect host physiology locally and systemically 
( Begley et al., 2006; Jones et al., 2014; Joyce et al., 2014a). 
 
Even though critical role of BSH function has been realized, research on the structural basis of 
BSH function is limited.  To date, the structure of BSH has only been revealed from 
Bifidobacterium longum (Kumar et al., 2006) and Clostridium perfrigens (Rossocha et al., 2005).  
A BSH protein with broad substrate spectrum from Lactobacillus salivarius NRRL B-30514 was 
identified previously in our lab (Wang et al., 2012).  This L. salivarius BSH (lsBSH) hydrolyzes 
glycoconjugated and tauroconjugated bile salts effectively, whereas B. longum BSH and C. 
perfrigens BSH only have narrow substrate spectrum.  Therefore, lsBSH is an ideal candidate for 
structure-function analyses of BSH.  The structure of lsBSH was successfully in our previous 
study (Xu et al., 2016).  In this study, according to structure analysis of lsBSH, several residues 
were predicted to be important for enzyme activity or substrate specificity; those residues were 
subjected to amino acid substitution mutagenesis.  The BSH mutants were purified and their 
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activities were measured to examine the role of these residues in BSH activity and/or substrate 
specificity. 
 
Structural analyses of BSHs from various species would not only discover critical residues in 
catalysis and provide key information on the substrate specificity of BSHs, but also will directly 
facilitate future translational research, such as using molecular docking to develop BSH 
inhibitors-based alternatives to AGPs or BSH enhancers-based weight-reducing aids.  
 
Materials and methods 
Bacterial strain, plasmid, and compound 
The bacterial strains and plasmids used in this study and their sources are listed in Table 3-1.  A 
plasmid with bsh gene from L. salivarius NRRL B-30514 inserting in vector pET21b constructed 
in our previous work was used for aa substitution mutagenesis; the Escherichia coli recombinant 
strain JL885 constructed in our previous study, which harbors pBSH was used for wild-type 
lsBSH purification (Wang et al., 2012b).  The major information for the wild-type lsBSH and the 
lsBSH-producing strain JL885 is summarized in Table 3-2.  Ampicillin, as well as Glycocholic 
acid (GCA), glycodeoxycholic acid (GDCA), glycochenodeoxycholic acid (GCDCA), 
taurocholic acid (TCA), taurodeoxycholic acid (TDCA), and taurochenodeoxycholic acid 
(TCDCA) were purchased from Sigma-Aldrich (USA). 
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Site-directed amino acid (aa) substitution mutagenesis 
Based on structure analysis of lsBSH, amino acids sites that are important for lsBSH activity and 
substrate specificity (Xu et al., 2016).  The predicted amino acids in lsBSH that may be 
important for catalysis and substrate specificity were replaced with different amino acids using 
QuickChange II site-directed mutagenesis kit (Agilent Technologies, USA).  Briefly, the partial 
overlapping primer pairs containing the desired mutations (Table 3-3) were used for polymerase 
chain reaction (PCR) amplification with the pBSH plasmid.  The cycling conditions were as 
follows: 95°C for 30 seconds, followed by 12 (for single nuclide mutation), 16 (for single amino 
acid mutation), or 18 (for multiple amino acids deletion or insertion) cycles of 95 °C for 30 
seconds, 55 °C for 1 min, and 68 °C for as time needed (1 min/kb for extension), and then stayed 
at 4 °C until the next step.  The PCR products were treated with Dpn I restriction enzyme at 37 
°C for 1 hour to digest the methylated, non-mutated parental DNA template.  The digested 
products were transformed into XL1-Blue super competent cells and cell cultures were grown on 
LB agar plates with ampicillin (100 µg/mL).  Plates were incubated at 37 °C in an incubator 
overnight.  In the following steps, single colonies were incubated and plasmids were extracted.  
A plasmid with a specific aa substitution in pBSH was verified by sequencing (University of 
Tennessee Genomic Core).  Eight plasmids with different amino acids substitutions or deletion 
(Table 3-1) were generated and then transferred into E. coli BL21(DE3) competent cells, 
creating the constructs JL1189, JL1191, JL1193, JL1196, JL1198, JL1201, JL1203, and JL1205 
(Table 3-1).  These constructs and control strain JL885 were used for protein expression, 
purification, and two-step BSH activity assay to determine the roles of specific amino acids in 
lsBSH. 
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BSH activity assay 
The wild-type lsBSH and corresponding mutants were expressed and purified following the 
procedures detailed in the Materials and Methods section in Chapter II of this dissertation.  
Modified two-step standard activity assays were performed to determine enzyme activity and 
substrate specificity (Tanaka et al., 2000; Wang et al., 2012b).  Activity was expressed by the 
amount of free amino acids liberated from conjugated bile salts as substrates.  Ten microliters 
of purified enzymes (1 µg/µL), 10 µL of conjugated bile salts (GCA, GDCA, GCDCA, TCA, 
TDCA, TCDCA), 178 µL of reaction buffer (0.1 M sodium-phosphate, pH 6.0), and 2 µL of 1 
M DTT were mixed gently and incubated at 37 °C for 30 min.  Following the incubation, 
reaction tubes were put on ice to stop the reaction.  Then, 50 µL aliquot of the reaction 
mixture was mixed with 50 µL15% trichloroacetic acid (w/v) to fully stop the reaction, and 
the sample was centrifuged at 12,000 g for 5 min to remove the precipitate.  The supernatant 
was mixed thoroughly with 950 µL ninhydrin reaction mix (0.25 mL of 1% ninhydrin (w/v), 
0.1 mL sodium-citrate buffer (pH5.5), 0.6 mL glycerol) and incubated in boiling water for 14 
min.  The reactions were stopped by putting reaction tubs on ice for 3 min and the absorbance 
of reaction mix at 570 nm wavelength was read with a Smart Spec Plus spectrophotometer 
(Bio-Rad).  Standard curves using glycine or taurine were determined for each independent 
assay.  All assays were performed in triplicate.  Enzyme activity was expressed as 1 µmol of 
amino acids released from substrates per minute per mg of BSH (Wang et al., 2012b) and 
mutants relative activity compared to wild-type lsBSH was also calculated. 
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Results  
Structural analysis of lsBSH 
In a previous study, a 1.90 Å resolution crystal structure of lsBSH was obtained and it belongs to 
the N-terminal nucleophile hydrolase superfamily (Xu et al., 2016).  Based on the comparison of 
the crystal structure of lsBSH with previously published structure from Clostridium perfrigens 
and Bifidobacterium longum (Kumar et al., 2006; Rossocha et al., 2005), these three BSHs 
shared similar conserved catalytic active center at Cys2 and its coordinated neighbor amino acids 
(Xu et al., 2016).  However, several other surrounding amino acids were significantly different 
which may contribute to enzyme activity and specificity towards glycine and taurine conjugated 
bile salts (Table 3-4).  It was speculated that in loop I, Tyr24 along with Phe65 at the bottom of 
the binding pocket force the substrates to sit deeply in the binding pocket, which may contribute 
to the increase of lsBSH activity.  Leu18 and Phe22 in loop I may contribute to different 
enzyme-substrate interaction which probably is the reason that lsBSH has a broader substrates 
spectrum.  On loop II, Leu134 and Phe130 residues may contribute to restraint of the spatial 
configuration by condensing the substrate-binding pocket entrance.  Two residues, Ile56 and 
Leu63, at the bottom of the binding pocket may determine the different substrate specificities.  
Asn171 coordinates to Cys2 and helps to stabilize Cys2 or transfer electron in catalysis.  
Substrate-enzyme interaction revealed that Gln257 and Glu270 may play an important role in 
stabilizing the reactant which makes lsBSH be able to digest taurine-conjugated bile salts. 
 
Together with BSH gene sequencing results from different bacteria sources, it was also 
speculated that the amino acid residues 164-171 play a role in maintaining the environment 
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around Cys2 and this residue may also play a significant role in substrate specificity (Fang et al., 
2009). 
 
Site-directed mutagenesis and protein purification 
Sequences of mutated plasmids were confirmed by DNA sequencing and a sequence 
chromatogram was performed in Chromas Lite 2.3 (Figure 3-4).  Mutated codons corresponding 
to designed amino acid sites were marked in black frame and mutated codons were marked with 
asterisks.  Sequencing results revealed that there were no additional mutations occurring on the 
genes except for the anticipated ones.  The SDS-PAGE gel also revealed that lsBSH and its 
mutants were properly expressed and purified with satisfactory purity (Figure 3-5). 
 
BSH enzyme activity of various BSH mutants for different bile salts 
The enzyme activity of eight purified BSH mutants was measured for six different conjugated 
bile salts and the activity of wild-type lsBSH was used as control (Table 3-5).  Site-directed 
mutagenesis of Cys2 in lsBSH almost abolished its activity towards all six tested bile salts.  The 
lsBSH with Cys2 mutation only displayed marginal BSH activity for TCA when compared to 
wild-type lsBSH.  Site mutation on Tyr24 led to dramatic activity decrease towards GCA and 
GDCA; enzyme activity towards tauroconjugated bile salts did not show dramatic difference 
relative to lsBSH.  The mutation of amino acid site of Phe65, which was predicted to force 
substrates to sit deeply in the binding pocket with Tyr24, showed similar enzyme activity with 
Tyr24 mutated BSH.  Mutation on Phe65 totally abolished the BSH activity for GCA and 
GDCA, leaving a marginal activity for GCDCA.  The enzyme activity for TCA and TDCA 
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decreased by 40%-50% compared to wild lsBSH, and enzyme activity for TCDCA was not 
affected. 
 
In the mutant with Asn171, which was speculated to be important for Cys2 function, mutation 
caused a dramatic decrease in BSH activity for all six bile salts; enzyme activity for GCA, 
GDCA, GCDCA, and TDCA was marginal and only 16.41% activity for TCDCA and 10.75% 
activity for TCA compared to wild-type lsBSH was left.  The deletion of the motif of amino acid 
residues of 164-171 caused a total cessation of BSH activity for all six bile salts. 
 
Mutation at Gln257 did not show a dramatic difference in taurocongugated bile salts (TCA, 
TDCA, TCDCA), but the activity for glycoconjugated bile salts was decreased by 90% to 75%.  
Mutation on Glu270 did not cause a big difference in BSH activity towards all six substrates.  
However, the double mutation of Gln257 and Glu270 caused a conspicuous enzyme activity 
decrease for all six substrates, the decrease ranging from 65% to 95% relative to wild-type 
lsBSH. 
 
Discussion 
Based on the structure of lsBSH, several residues that may either be important for BSH activity 
or substrate specificity were predicted.  The major amino acid residues predicted that are 
involved in lsBSH catalysis and substrate specificity (Table 3-4) were revealed for the first time 
other than the six predicted BSH conservative sites (Cys-2, Arg-16, Asp-19, Asn-79, Asn-171, 
and Arg-224).  Within these predicted residues, Asn171 and motif 164-171 showed the strongest 
effect on BSH activity, which was consistent with our prediction that they help Cys2 
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stabilization or electron transfer and manipulation of the environment around Cys2.  Together 
with the finding that Cys2 mutation totally abolished BSH activity, it was also confirmed that 
BSH, the member in Ntn hydrolase family, has Cys2 in its active center for catalysis.  Residues 
interacting with Cys2 might have a profound effect on enzyme activity.  However, the exact 
mechanism for the effects needs further confirmation by structure-function analysis. 
 
The lsBSH has a broader substrates spectrum and can efficiently hydrolyze both glycoconjugated 
and tauroconjugated bile salts relative to BSH from other bacterial sources which have a higher 
activity towards glycoconjugated bile salts (Kumar et al., 2006; Rossocha et al., 2005).  Our 
structure analysis predicted that Gln257 and Glu270 may play a role in stabilizing the taurine 
group, which contributed to the potent lsBSH activity towards tauroconjugated bile salts.  
However, the mutagenesis and enzyme activity assay did not show dramatic activity decrease 
specific towards taucoconjugated bile salts.  This mis-predication was probably caused by the 
technical difficulty of structure-substrates analysis.  Our prediction was based on the interaction 
between taurine and lsBSH.  The size of glycine is too small for structure-substrates analysis.  
The residues predicted to be important for tauroconjugated bile salts may also be important for 
glycoconjugated bile salts. 
 
The structure analysis on the broad substrates spectrum lsBSH provided a solid foundation for 
BSH structure analysis, which is helpful for future transnational research.  Due to the significant 
role of BSH in host physiology, BSH can be a novel target to control host body weight and lipid 
metabolism (Geng et al., 2016; Joyce et al., 2014a).  With increasing over-weight and obesity 
rates in the world, BSH enhancers would be promising in controlling host lipid metabolism and 
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body weight.  In agriculture, BSH inhibitors would be potential antibiotic growth promoters 
alternative to promote the growth of farm animals.  Future research in screening BSH inhibitors 
and enhancers would be really beneficial for human and animal health.  
 
These BSH inhibitors and enhancers can be developed by molecule docking, which would 
dramatically increase hits rather than using standard chemical library (Taylor et al., 2002; Yuriev 
et al., 2015; Yuriev et al., 2013).  Current development in machine learning also improved the 
docking accuracy (Ain et al., 2015).  With the successful expression and purification of lsBSH 
mutants in this study, the future crystallization of mutants would also provide new aspects of 
BSH interaction between its substrates or enzyme inhibitors and enhancers.  Those hits by 
molecule docking can be validated with our established high-throughput screening system 
(Smith et al., 2014) and those chemicals with outstanding enhancing or inhibiting effects on BSH 
would be used for further in vivo and in vitro experiments to validate their physiological roles. 
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Table 3- 1. Key bacterial plasmids and strains used in this study. 
Plasmids or 
strains 
Description Source or 
Reference 
Plasmids   
pBSH 
pET21b containing bsh gene from Lactobacillus 
salivarius NRRL B-30514, Ampr 
(Wang et al., 
2012b) 
pBSH (C2S) pBSH derivative with C2S mutation in BSH This study 
pBSH (Y24F) pBSH derivative with Y24F mutation in BSH This study 
pBSH (F65A) pBSH derivative with F65A mutation in BSH This study 
pBSH (N171A) pBSH derivative with N171A mutation in BSH This study 
pBSH (164-171) pBSH derivative with motif 164 to 171 amino acid 
deletion in BSH 
This study 
pBSH (Q257A) pBSH derivative with Q257A mutation in BSH This study 
pBSH (E270A) pBSH derivative with E270A mutation in BSH This study 
pBSH (Q257A 
E270A) 
pBSH derivative with double mutations (Q257A and 
E270A) in BSH 
This study 
   
Strains   
E.coli BL21(DE3) F– ompT gal dcm lon hsdSB(rB- mB-) λ(DE3 [lacI 
lacUV5-T7 gene 1 ind1 sam7 nin5]) 
Novagen 
E.coli XL1-Blue EndA1 gyrA96(nalR) thi-1 recA1 relA1 lac glnV44 
F'[ ::Tn10 proAB+ lacIq Δ(lacZ)M15] hsdR17(rK- mK+) 
Agilent 
Technologies 
JL885 E.coli BL21(DE3) containing the plasmid pBSH  (Wang et al., 
2012b) 
JL1189 E.coli BL21(DE3) containing the plasmid pBSH (C2S) This study 
JL1191 E.coli BL21(DE3) containing the plasmid pBSH 
(Y24F) This study 
JL1193 E.coli BL21(DE3) containing the plasmid pBSH 
(F65A) 
This study 
JL1196 E.coli BL21(DE3) containing the plasmid pBSH 
(N171A) This study 
JL1198 E.coli BL21(DE3) containing the plasmid pBSH (164-
171) 
This study 
JL1201 E.coli BL21(DE3) containing the plasmid pBSH 
(Q257A) 
This study 
JL1203 E.coli BL21(DE3) containing the plasmid pBSH 
(E270A) 
This study 
JL1205 E.coli BL21(DE3) containing the plasmid pBSH 
(Q257A E270A) 
This study 
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Table 3- 2. Key background information for the lsBSH produced by the recombinant E. 
coli JL885. 
Parameters  Corresponding information 
Source organism  Lactobacillus salivarius NRRL B-30514 
DNA source  Genomic DNA 
Forward primer a  5'-CGCGGATCCATGTGTACAGCAATTACTTT-3' (BamHI) 
Reverse primer a  5'-CCGCTCGAGATTCAACTTATTTATTATTTGT-3' (XhoI) 
Cloning vector  pET-21b  
Expression vector  pET-21b 
Expression host  E. coli BL-21(DE3) 
Complete amino 
acid sequence of 
the construct 
produced b 
MCTAITLNGNSNYFGRNLDLDFSYGEEVIITPAEYEFKFRKEKAI
KNHKSLIGVGIVANDYPLYFDAINEDGLGMAGLNFPGNAYYSD
ALENDKDNITPFEFIPWILGQCSDVNEARNLVEKINLINLSFSEQL
PLAGLHWLIADREKSIVVEVTKSGVHIYDNPIGILTNNPEFNYQ
MYNLNKYRNLSISTPQNTFSDSVDLKVDGTGFGGIGLPGDVSPE
SRFVRATFSKLNSSKGMTVEEDITQFFHILGTVEQIKGVNKTESG
KEEYTVYSNCYDLDNKTLYYTTYENRQIVAVTLNKDKDGNRL
VTYPFERKQIINKLNLERHHHHHH 
 
a Restriction sites in the forward and reverse primers sequences are underlined, and the 
restriction enzymes are indicted in parentheses.  
b The His-tag site is underlined.  
The original information of lsBSH was introduced in a previous publication (Wang et al., 
2012b).  
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Table 3- 3. The primers used for site-directed aa substitution mutagenesis in this study. 
Primer Name Sequence 5`-3` a 
BSHMT1-F CCATTTAAAGTAATTGCTGTAGACATGGATCCCGACCCATTT 
BSHMT1-R AAATGGGTCGGGATCCATGTCTACAGCAATTACTTTAAATGG 
BSHMT2-F 
GATTACCTCCTCACCAAATGAAAAATCTAAATCTAAGTTTCTTCCA
A 
BSHMT2-R 
TTGGAAGAAACTTAGATTTAGATTTTTCATTTGGTGAGGAGGTAA
TC 
BSHMT3-F 
TCCATCCTCATTAATAGCATCTGCATACAATGGGTAATCGTTAGCG
ACAATTCC 
BSHMT3-R GGAATTGTCGCTAACGATTACCCATTGTATGCAGATGCTATTAATG
AGGATGGA 
BSHMT4-F CAGATTGTACATCTGATAATTAAATTCTGGATTTGCAGTCAATATT
CCAATTGG 
BSHMT4-R  CCAATTGGAATATTGACTGCAAATCCAGAATTTAATTATCAGATG
TACAATCTG 
BSHMT5-F GTACATCTGATAATTAAATTCTGGATTATCATAAATATGTACTCCA
GATTTAGTTACTTC 
BSHMT5-R GAAGTAACTAAATCTGGAGTACATATTTATGATAATCCAGAATTT
AATTATCAGATGTAC 
BSHMT6_Q2
57A-F 
CCATATACTAGGGACAGTAGAAGCAATAAAGGGCGTTAATAAGA
CAG 
 
BSHMT6_Q2
57A-R 
CTGTCTTATTAACGCCCTTTATTGCTTCTACTGTCCCTAGTATATGG 
 
BSHMT7_E2
70A-F 
GACAGAATCAGGAAAAGAAGCATACACTGTATATTCGAATTGC 
 
BSHMT7_E2
70A-R 
GCAATTCGAATATACAGTGTATGCTTCTTTTCCTGATTCTGTC 
 
 
a Bolded letters indicate the nucleotides designed for aa substitution mutagenesis.  
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Table 3- 4. Major amino acid residues of lsBSH that are potentially involved in catalysis 
and substrate specificity based on comparative structural analysis. 
Residue Specific location Speculation  
Tyr24 Loop I Along with Phe65, may force the substrate to sit 
deeply in the binding pocket 
Leu18 Given their differences when compared with the 
structures of cpBSH and blBSH, they may contribute 
to different enzyme–substrate interactions 
Phe22 
Leu134 Loop II Both residues contribute to restraint of the spatial 
configuration by condensing the substrate-binding 
pocket entrance 
Phe130 
Ile56 Bottom of the 
binding pocket 
Compared with the structures of cpBSH and blBSH, 
these two residues may determine the differing 
substrate specificities 
Leu63 
Phe65 Along with Tyr24, may force the substrate to sit 
deeply in the binding pocket 
Asn171  Coordinate to Cys2 and help to stabilize Cys2 or 
transfer electron in catalysis 
Gln257  These two sites plays an important role in stabilizing 
the reactant  Glu270  
164-171  This residue may play a role in substrate specificity 
and rBSH activity by manipulation environment 
around Cys2 
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Table 3- 5. Comparison of BSH enzyme activity of various BSH mutants for different bile salts. 
Exp 
No.b BSH 
BSH activitya 
GCA GDCA GCDCA TCA TDCA TCDCA 
1 
WT 2.4±0.04 (100) 
1.4±0.07 
(100) 
5.4±0.27 
(100) 
5.3±0.15 
(100) 
5.5±0.15 
(100) 
5.3±0.07 
(100) 
Cys2Ser − − − 0.16±0.02 (3.02) − − 
Tyr24Phe 1.9±0.09 (79.17) 
1.0±0.00 
(71.43) 
6.4±0.22 
(118.59) 
5.3±0.03 
(100) 
5.5±0.02 
(100) 
5.3±0.08 
(100) 
Phe65Ala − − 0.2±0.01 (3.70) 
3.4±0.07 
(64.15) 
2.9±0.11 
(52.73) 
5.4±0.07 
(101.89) 
Asn171Al
a 
0.17±0.05 
(7.08) 
0.05±0.00 
(3.57) 
0.22±0.01 
(4.07) 
0.57±0.03 
(10.75) 
0.26±0.01 
(4.73) 
0.87±0.05 
(16.41) 
Δ164-171 − − − − − − 
 
2 
WT 1.47±0.17 (100) 
0.97±0.11 
(100) 
2.74±0.03 
(100) 
1.28±0.11 
(100) 
1.32±0.10 
(100) 
1.31±0.09 
(100) 
Gln257Ala 0.37±0.014 (25.17) 
0.16±0.02 
(16.49) 
0.38±0.05 
(13.87) 
1.26±0.014 
(98.44) 
1.27±0.09 
(96.21) 
1.22±0.06 
(93.13) 
Glu270Ala 2.35±0.09 (159.86) 
0.77±0.02 
(79.38) 
2.84±0.05 
(103.65) 
1.29±0.011 
(100.78) 
1.38±0.19 
(104.55) 
1.34±0.01 
(102.29) 
Gln257Ala 
Glu270Ala 
0.4±0.02 
(27.21) 
0.11±0.02 
(11.34) 
0.19±0.02 
(6.93) 
0.45±0.13 
(35.16) 
0.15±0.06 
(11.36) 
0.22±0.004 
(16.79) 
 
a The BSH activity was expressed as µmol of amino acids released from the substrate per minute per mg of BSH (µmol/min/mg ).  The 
activity of following six  bile salt substrates were tested: glycocholic acid (GCA), glycodeoxycholic acid (GDCA), 
glycochenodeoxycholic acid (GCDCA), taurocholic acid (TCA), taurodeoxycholic acid (TDCA), taurochenodeoxycholic acid 
(TCDCA).  Experiments were carried out in triplicate.    The numbers in parentheses indicate the relative activity (%) of the activity of 
specific BSH mutant when comparing with that of wild-type (Ou et al., 2013) BSH enzyme. “−” represents no BSH activity detected 
(no significant difference when comparing with negative control) 
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b Two independent experiments were performed.  For each independent experiment, all BSHs were purified in parallel under same 
condition and the freshly purified enzymes were subjected to BSH activity assay.  
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Figure 3- 1. Sequence chromatogram of confirmed site directed mutagenesis of BSH. 
Sequence chromatogram of confirmed site directed mutagenesis of BSH. Black frame marked 
the mutations in plasmids and mutated codons were marked with asterisks in corresponding sites. 
(a) Sequence chromatogram of plasmid pBSH (C2S) and pBSH (Y24F) compared to wild type 
pBSH. (b) Sequence chromatogram of plasmid pBSH (F65A) compared to wild type pBSH. (c) 
Sequence chromatogram of plasmid pBSH (N171A) and pBSH (164-171) compared to wild type 
pBSH.  (d) Sequence chromatogram of plasmid pBSH (Q257A) and pBSH (E270A) compared to 
wild type pBSH. Sequences presented were the reverse compliment of original sequence. Amino 
acid site 257 mutation from CTG to TGC represents Gln (CAG) to Ala (GCA). Amino acid sit 
270 mutation from TTC to TGC represents Glu (GAA) to Ala (GCA). (e)  Sequence 
chromatogram of double sites mutated plasmid pBSH (Q357A E270A).  Sequences presented 
were the reverse compliment of original sequence. Amino acid site 257 mutation from CTG to 
TGC represents Gln (CAG) to Ala (GCA). Amino acid sit 270 mutation from TTC to TGC 
represents Glu (GAA) to Ala (GCA). 
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Figure 3- 1. Continued. 
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Figure 3- 1. Continued. 
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Figure 3- 1. Continued. 
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Figure 3-2. Expression and purification of wild type lsBSH and its mutants. 
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Chapter IV. In vivo evaluation of bile salt hydrolase inhibitors physiological 
roles using broiler chicken
115 
  
Abstract 
 Recent studies strongly suggest that bile salt hydrolase (BSH) inhibitors may serve as innovative 
alternatives to antibiotic growth promoters (AGPs) for sustainable animal production.  A panel of 
promising BSH inhibitors also have been identified in our recent study.  However, it is still 
unknown if dietary supplementation of the identified BSH inhibitors can really inhibit the 
activity of the BSH enzyme in the intestine, and lead to significant changes in bile profile as well 
as host physiology.  Understanding of the in vivo efficacy of the BSH inhibitor is critically 
needed for us to develop effective non-antibiotic feed additives for commercial applications.  In 
this study, the effects of dietary supplementation of three BSH inhibitors, caffeic acid 
phenethylester, riboflavin, and carnosic acid, were evaluated in broilers.  Forty newly hatched 
Hubbard broiler chickens received water and standard basal chicken feed ad libitum throughout 
the study.  From 7 days of age, the chicks were assigned into 4 groups (10 chickens per group) 
that one group received control solution and the each of the other three groups received three 
different BSH inhibitors (25 mg/kg body weight) via oral gavage for 17 days.  Despite 
significant body weight variation among individual birds in each group, the broilers in all three 
treatment groups showed consistently higher body weight and body weight gain compared to 
chicken from the control group, but the difference was not statistically significant.  
Metabolomics analysis of intestinal samples using UPLC-MS showed significant changes in bile 
acid (BA) profiles in response to BSH inhibitor treatment, demonstrating in vivo efficacy of the 
BSH inhibitors.  There was no significant difference among the groups in terms of the levels of 
serum biochemical parameters.  However, transcriptome analyses of liver and intestine samples 
indicated that carnosic acid treatment led to significant differential expression of those genes 
involved in lipid metabolism and bile acid metabolism.  Together, the findings from this study 
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demonstrated in vivo efficacy of the identified BSH inhibitors, which is a significant step toward 
our long-term goal of developing effective BSH inhibitor-based alternatives to AGPs. 
Keywords: Bile salt hydrolase inhibitor, in vivo efficacy, bile profile, RNA-Seq 
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Introduction 
Antibiotic growth promoters (AGPs), a group of low-dose antibiotics, have been widely used as 
feed additives for more than six decades to increase feed efficiency, energy harvest and body 
weight gain of food animals (Moore et al., 1946).  However, due to a potential link bewteen 
AGP usage and antimicrobial resistance (AMR), there is a worldwide trend to limit the use of 
AGPs to mitigate AMR and enhance food safety (Dibner et al., 2005; Turnidge, 2004).  To 
maintain current animal production without threatening the public health, it is urgent to develop 
effective alternatives to AGPs. 
 
In turn, developing effective alternatives to AGPs makes it essential to understand the 
mechanisms of AGPs.  Of various proposed such mechanisms, the AGPs mediated modulation 
of  intestinal bacteria is a major one (Brown et al., 2017).  In particular, recent microbiome 
studies provided compelling evidence that intestinal bacterial bile salt hydrolase (BSH), which is 
affected by AGP usage and negatively correlated to host energy harvest and lipid metabolism, is 
a promising microbiome target for developing novel alternatives to AGPs (Lin, 2014).  
Specifically, the small compounds that can inhibit BSH activity may function similarly as AGPs 
for enhanced feed efficiency and growth performance. 
 
Recently, we identified and characterized a BSH enzyme with broad substrate specificity isolated 
from a Lactobacillus salivarius strain from chicken intestine (Wang et al., 2012b).  With this 
ideal candidate, we identified and characterized a group of promising BSH inhibitors using an 
effective High-Throughput Screening (HTS) system (Smith et al., 2014).  Among these BSH 
inhibitors, riboflavin is a vitamin participating in a range of redox reactions in the host (Massey, 
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2000; Powers, 2003).  In a recent study, the riboflavin level in feed was observed to influence  
animal behavior and growth (Qi et al., 2017).  In addition, dietary supplementation of riboflavin 
was shown to increase feed efficiency and body weight gain in pigs (Stahly et al., 2007).  The 
caffeic acid phenethylester (CAPE), a potent BSH inhibitor, was originally  discovered as a 
bioactive component in propolis from honeybee hives (Bankova, 2005).  The CAPE has shown 
multiple bioactivities, such as anti-tumor, anti-oxidation, anti-inflammatory, and immune 
regulation (Zhang et al., 2014a); however, its effect on host lipid metabolism or growth 
performance was limited.  The other BSH inhibitor carnosic acid is a phenolic terpene extracted 
from rosemary and sage which was claimed to have anti-oxidant, anti-inflammatory, and anti-
carcinogenic activities (Bahri et al., 2016; de Oliveira, 2016; Naimi et al., 2017; Tolba et al., 
2013).  Both in vitro and in vivo experiments showed that carnosic acid is involved in glucose 
and lipid metabolism (Ninomiya et al., 2004). 
 
It is hypothesized that oral administration of these three promising BSH inhibitors will exert 
inhibitory effect on intestinal BSH activity, thus leading to significant changes in bile profiles as 
well as host physiology.  Therefore, this study investigated the effects of oral administration of 
the three BSH inhibitors on host physiology using broilers.  Chicken bile salt profile, lipid 
metabolism, and growth performance were analyzed.  Transcriptome analyses using different 
pipelines and statistical models were also conducted to reveal molecular mechanisms in response 
to carnosic acid treatment. 
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Materials and methods 
Animal experiment 
The process of chicken experiment followed the University of Tennessee Institutional Animal 
Care and Use Committee protocol (IACUC # 2187).  Forty newly hatched male broilers from 
Hubbard LLC in Pikeville, TN were raised in the Joseph E. Johnson Animal Research and 
Teaching Unit (JARTU, Knoxville, TN, USA).  After one week, chicks were randomly allocated 
into four groups (10 birds per group).  During the 28 days of experiment period, one group 
(control) received 50% propylene glycol; the second group received riboflavin (Bulk 
Supplements, Henderson, NV, USA); the third group received carnosic acid (Purify, Chengdu, 
Sichuan, China) and the fourth group received caffeic acid phenethyl ester (Wuhan Yuancheng 
Gongchuang Tech, Wuhan, Hubei, China).  The administration method was daily oral gavage.  
Solutions of riboflavin, carnosic acid and CAPE were prepared by dissolving 700 mg compound 
into 10 mL solvent (water: propylene glycol = 1:1, v/v).  Gavage dosage was equivalent to 25 mg 
compounds per kilogram of chicken and dosage was adjusted by chicken body weight on days 7, 
10, 14, 17, 21, and 24.  The chicken feed used in this project was All Natural Meat Bird Start 
Feed purchased from Co-op Feeds (#91107).  Water and feed were available ad libitum during 
the project.  On days 7, 10, 14, 17, 21, 24, and 28, the bird body weights were measured.  Feed 
dropped on the pans of the cages was collected as much as possible to provide accurate feed 
intake value and feed conversion ratio data.  Due to an unrecorded chicken feed intake at 9-day 
of chicken age, we started recording chicken feed in and out from day 10; feed intake and body 
weight data were recorded twice a week. On days 10, 14, 17, 21, 24 and 28 chicken feed 
consumption per cage was measured and feed conversion ratio (feed intake/body weight gain) 
was also determined.  On day 28, all birds were sized bird per pen was further selected for sample 
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collection.  Following blood collection from the wing vein, the birds were euthanized with carbon 
dioxide and about 1 mL chicken blood from wing vein was collected from each chicken; chicken 
feces were also collected as duplicates in 1.5 mL Eppendorf tubes and placed on ice; about 5 cm 
of chicken ileum from each chicken was collected and rinsed with saline (0.9% sodium chloride, 
w/v); chicken liver samples were also collected.  After sample collection, liver and ileum were 
wrapped in aluminum foil and then saved in liquid nitrogen immediately; blood samples were 
centrifuged at 4,000 g for 15 min; and the supernatant (serum) was transfer into sterile 1.5 mL 
Eppendorf tubes.  All collected samples were stored in -80 °C freezer before further analysis. 
 
Serum biochemical analyses 
Serum concentrations of glucose, triglycerides, total cholesterol, and very low-density 
lipoprotein were determined with corresponding kits following standard protocol (glucose and 
triglyceride, Cayman Chemical, Ann Arbor, MI, USA; total cholesterol, Bioassay System, 
Hayward, CA, USA; VLDL, Novatein Biosciences, Woburn, MA, USA). 
 
Bile profiles analyses 
Chicken fecal samples (about 0.5 g) and serum samples (200 µL) from all four treatment groups 
(10 chickens/group) were packed with dry ice and shipped to Dr. Susan Joyce (APC Microbiome 
Institute, University College Cork, Ireland) for bile acid profile analysis.  The metabolomics 
analysis was performed by Ultra Performance Liquid Chromatography-Tandem Mass 
Spectrometry (UPLC-MS); the detailed procedures for bile acids extraction, characterization and 
quantification were described in a previous publication (Joyce et al., 2014a).  Notably, our 
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collaborators did not know the specific treatment for each group; therefore, the ‘blinded’ 
metabolomics measurements ensure the quality of this collaborative work. 
  
RNA extraction 
Total RNA from liver and ileum samples of four chickens from the control group and the 
carnosic acid group was extracted with Qiagen RNeasy mini kit (Cat#: 74104, Qiagen, 
California, USA) following the standard protocol.  Then, the RNA integrity number (RIN), 
concentration and the 28S/18S ratio of RNA were evaluated with Agilent RNA 600 Nano kit 
using Agilent 2100 Bioanalyzer (genomics Hub, UTIA).  The total RNA was stored at -80 ℃ 
prior to use. 
 
Transcriptome sequencing 
Ten microliters of total samples extracted from chicken liver and ileum were packed in a dry ice 
box, which was shipped to the DNA facility of the Iowa State University Office of 
Biotechnology for mRNA-Seq libraries construction and transcriptome sequencing.  The 
concentrations of each total RNA samples are presented in Table 4-6.  The mRNA-Seq libraries 
were constructed based on high sample protocol in the TruSeq® RNA sample preparation v2 
guide.  Overall, sixteen sequencing libraries were constructed from RNA samples.  All mRNA-
Seq libraries were loaded into a single lane of the Illumina Hiseq 3000 system.  However, 
samples LC1, LC4, and IC2 showed really low reads and mapping rates after the first run.  
Therefore, these three samples were subjected to RNA-Seq again using the same procedure 
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except that the mRNA-Seq libraries were constructed based on low sample protocol in the 
TruSeq® RNA sample preparation v2 guide. 
 
RNA-Seq data process and analyses 
The RNA-Seq analyses were performed using two different pipelines.  The overview of RNA-
Seq data processing pipeline is summarized in Figure 4-1.  Regarding the RNA-Seq analysis 
performed in the Office of Advanced Research Computing at Rutgers University (NJ, USA), the 
raw reads were quality trimmed using Trimmomatic-0.33 with leading and trailing Q score 25, 
minimum length 25 bp, and minimum length 50 bp.  The cleaned reads were mapped to 
Gallus_gallus genome - 5.0 version, using Tophat v.2.0.13.  The reference genome sequence and 
annotation files were downloaded from ENSEMBLE, release.87 (Gallus_gallus.Gallus_gallus-
5.0.dna.toplevel.fa and Gallus_gallus.Gallus_gallus-5.0.87.gtf).  The aligned read counts were 
obtained using htseq-count as part of the package HTSeq-0.6.1. 
 
The RNA-Seq analysis performed at The University of Tennessee, Knoxville (UTK) is described 
below. Short raw reads were performed for quality assessment with FastQC v 0.11.5.  Then the 
raw reads were trimmed using Skewer and the trimmed data were processed for quality 
assessment again with MultiQc v 1.2.  The reads that passed filtering were aligned to 
Gallus_gallus NCBI build 5.0 reference genome with STAR v 2.3.0.  The alignment process 
produced a SAM (Sequence Alignment/Map) format file, which need to be processed with SAM 
tools and a table of gene read counts was generated using HTSeq v 0.9.1.  Raw reads quality 
assessment was performed on the Newton High Performance Computer (HPC) at UTK.  The 
123 
  
mapping and gene reads counting were performed on the Advanced Computing Facility (ACF) at 
UTK. 
 
The Bioconductor packages edgeR_3.8.6 with limma_3.22.7 and DESeq2 v 1.18.0 were used to 
perform the differential gene expression analysis in R Studio v 1.0.143.  For the differentially 
expressed genes (DEGs), corresponding P-values and fold changes were uploaded to DAVID 
Bioinformatics Resources (https://david.ncifcrf.gov/) online bioinformatics analysis system for 
functional annotation and canonical pathway analyses.  The detailed statistic model used in two 
Bioconductor packages were described in the Statistical Analyses section in this chapter. 
 
Reverse transcription and quantitative PCR assay 
The DEGs involved in immune response, bile acids metabolism, glucose metabolism, and lipid 
metabolism, as identified by the DAVID-BR analysis were also examined for the expression by 
performing qPCR analysis.  These genes include those encoding aldo-keto reductase family1 
(AKR1D1), cytochrome P450, family 3, subfamily A, polypeptide 80 (CYP3A80), glutathione 
S-transferase alpha 3 (GSTA3) in the liver and glutathione S-transferase alpha 3 (GSTA3), and 
G0/G1 switch 2 (G0S2) in the ileum.  Ileum and liver RNA samples from four individual birds of 
each group were used.  Two hundred micrograms of total RNA from each sample were used for 
cDNA synthesis using Thermo Scientific RevertAid First Strand cDNA synthesis kit (Cat#: 
K1621) according to the manufacturer instructions.  The qPCR assays were performed using 
iTaqTM universal SYBR Green Supermix (Bio-Rad Laboratories, Hercules, CA, USA).  Briefly, 
cDNA was diluted 100-fold, and 1 µL of each diluted sample was added to 10 µL volume 
reaction, also containing 1 µL of each forward and reverse primers of the target genes (50 ng/µL) 
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and 5 µL PCR master mix.  The primers of the target genes were designed using NCBI primer 
blast with corresponding mRNA sequences and the sequencing for primers are summarized in 
Table 4-1.  The β-actin gene was used as an internal reference to normalize target gene transcript 
levels since this is a commonly used house-keeping gene as an internal control for gene 
expression (De Boever et al., 2008).  The qRT-PCR was conducted in triplicate and the mean 
values were used for analysis.  Fluorescence measurements were collected after each annealing 
step.  The threshold cycle (CT) values for genes of interest were normalized to an average CT 
value of the house-keeping genes and the relative expression of replicate was calculated by the 2-
ΔΔCt method. 
 
Statistical analysis 
Chicken body weight, body weight gain, feed conversion ratio; serum levels of glucose, total 
cholesterol and triglycerides, and bile salts profile were compared among groups using mixed 
model analysis of variance procedure.  The statistical analysis of bile salts profile was conducted 
independently by our collaborator at University College Cork and by our laboratory.  These 
analyses were conducted with SAS v9.4 (SAS Institute, Cary, NC, USA) and least square means 
were compared at the significance level of P less than 5% (0.05).  For DEGs analysis, animal 
tissue and treatment were fixed effects fit in design model and individual animal was used as 
replicates when using the edgeR package.  Two different statistical design models were used 
when using the Deseq2 package.  In the first design, animal tissue and treatment were used as 
fixed effects in the design model and individual animal was used as replicates.  In the second 
design animal, animal tissue, and treatment were used as fixed effects to fit in the design model.   
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Results 
Growth performance in response to BSH inhibitors treatment 
All chickens exhibited normal growth behavior and there was no mortality during the 28 days of 
the experiment period.  As shown in Table 4-2, there was no statistical difference of chicken 
body weight and weekly body weight gain among four different groups (P > 0.05).  As for feed 
conversion ratio (FCR), from the experiment day 10 to 14, chickens in the riboflavin treatment 
group had a significantly higher FCR than chicken in the CAPE treatment group and carnosic 
acid treatment group (P = 0.0297); the difference in FCR among control group, CAPE treatment 
group, and carnosic acid treatment group was not statistically different (P > 0.05).  FCR from 
day 14-17, 17-21, 21-24 and 24-28 did not show a significant difference among all groups (P > 
0.05). 
 
Biochemical analyses of serum samples 
The effects of BSH inhibitors on chicken serum metabolites are shown in Table 4-3.  BSH 
inhibitors treatment did not cause significant difference of chicken serum glucose (P = 0.08), 
total cholesterol (P = 0.33), triglycerides (P = 0.85) and VLDL (P = 0.18) compared to the 
control group. 
 
Bile salts profile alteration in chicken fecal and serum samples in response to BSH 
inhibitor treatment 
The statistical analysis of the bile salts profile conducted by our collaborator at University 
College Cork and by our lab showed the same results. 
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Ten chicken fecal samples from each of the four groups were subjected to bile profile analyses 
by UPLC-MS.  Twenty-six bile acids and amino acids related to bile metabolism were qualified 
and quantified (Table 4-4).  Representative bile profiles obtained from chicken fecal samples in 
response to BSH inhibitors treatment are presented in Figure 4-2.  BSH inhibitors treatment in all 
three groups had lower murocholic acid concentration than the control group, but only 
murocholic acid concentration in chicken fecal samples from the riboflavin treatment group was 
statistically significant lower than the control group (P = 0.04).  Similarly, chicken fecal 
lithocholic acid (LCA), glycohyodeoxycholic acid (GHCA), and glycodeoxycholic acid 
(GCDCA) concentrations decreased corresponding to BSH inhibitor treatments, but riboflavin 
treatment also caused the largest change (P < 0.05).  The concentration of glycoursodeoxycholic 
acid (GUDCA) decreased in response to BSH inhibitors treatment, but it was at a marginally 
significant level (P = 0.06).  The concentration of secondary and tertiary bile salts also decreased 
in BSH inhibitors treatment groups compared to the control group, and only riboflavin treatment 
group showed the significant decrease (P = 0.03).  Notably, taurine concentration, an indication 
of bile salts deconjugation, was lower in all three BSH inhibitors treatment groups than in the 
control group, however, the difference was not significant.  There was no statistical difference 
shown among the other bile salts (P > 0.05). 
 
Using the same process, all ten chicken serum samples from each of the four groups were 
subjected to bile profile analyses by UPLC-MS.  Twenty-six bile acids and amino acids related 
to bile metabolism were determined and quantified (Table 4-5).  Of the tested bile salts, 
riboflavin treatment caused a significantly low concentration of glycohyocholic acid (GHCA) in 
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serum compared to the control group and carnosic acid treatment group (P = 0.01).  However, 
there was not a statistical difference among four groups for other bile salts (P > 0.05). 
 
General analysis of gene expression profiles among different samples 
RNA-Seq data analysis was successfully performed by our collaborator Dr. Janet Chang 
(Rutgers University) using the established software and package in the core facility at her 
institution.  However, due to the supercomputer system’s transformation from HPC to ACF at 
UTK, some technical issues arose and we were not able to process RNA-Seq mapping and gene 
reads counting process using UTK’s ACF supercomputer system.  Instead, we used the gene 
count data generated by our collaborator and processed the DEGs analysis with DESeq2 package 
in R as shown in Figure 4-1. 
 
The concentration and RIN (Table 4-6) implied high quality of extracted RNA.  More than 685 
million raw reads in pairs were obtained from RNA-Seq, ranging from 9.2 to 162.7 M raw reads 
per sample; both the numbers of raw reads and trimmed reads are presented in Table 4-6.  The 
mapping rate of RNA samples from liver samples and ileum samples ranged from 61.2% to 
88.2%.  The number of DEGs caused by carnosic acid treatment in liver and ileum samples were 
analyzed by edgeR and DeSeq2 package, the number of DEGs from three different methods 
presented in Table 4-7 and the Venn diagram (Figure 4-3) revealed the different number of 
DEGs determined by three different methods.  The number of DEGs in the liver (up regulated 
and down regulated) were more than the DEGs in the ileum (up regulated and down regulated).  
The representative DEGs in response to carnosic acid were summarized in Table 4-8. 
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Validation of DEGs by quantitative PT-PCR (qRT-PCR) 
The expression of DEGs involved in bile acid metabolism and lipid metabolism in the liver or 
ileum, as identified by DAVID-BR, was further validated using qRT-PCR.  All the tested genes 
showed the same pattern in their expression levels in both qPCR and RNA-Seq analysis (Table 
4-9), indicating successful completion of RNA-Seq analysis. 
 
Discussion 
BSH takes part in the gateway reaction of bile acid metabolism by the deconjugation of 
conjugated bile acid and production of unconjugated bile acid and free amino acids (taurine or 
glycine) (Begley et al., 2006).  The hypothesis of this study is that BSH inhibitors treatment 
would act on chicken intestinal bacterial BSH, which would further change the host bile profile.  
In this study, the oral administration of BSH inhibitors treatment caused chicken fecal bile 
profile changes, while the bile profile change in the serum samples was not as dramatic as in the 
fecal samples.  The decrease of taurine and increase of total conjugated bile acid (except in 
CAPE treatment group, Table 4-4) in fecal samples implied decreased BSH activity in the 
intestine.  Besides, the concentration of secondary and tertiary bile acids in fecal samples (Figure 
4-2) from all three BSH inhibitors treatment groups were lower compared to fecal samples from 
the control group.  This was due to the decreased unconjugated bile acids which are precursors of 
secondary and tertiary bile acids (Begley et al., 2006; Russell, 2009; Vlahcevic et al., 1996).  
The concentrations of murocholic acid (McAuliffe et al., 2005) and lithocholic acid (LCA) were 
also decreased significantly in the fecal samples from the BSH inhibitors treatment group (Table 
4-4, Figure 4-2).  Notably, LCA has long been recognized as a toxic component for different 
animals such as chickens and rabbits (Bernstein et al., 2005; Fischer et al., 1974; Hofmann, 
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1999; Leveille et al., 1964; Leveille et al., 1966).  The LCA was considered an implication of 
colon carcinogenesis (Bernstein et al., 2005) and highly hepatotoxic for experimental animals 
(Hofmann, 1999).  In previous studies, it was shown that when adding LCA to chicken feed, 
animal plasma lipid levels and liver size were increased and liver fat was decreased; the biliary 
hyperplasia in chicks was also induced (Leveille et al., 1964; Leveille et al., 1966).  The 
decreased LCA concentration in the fecal samples from the BSH inhibitor groups indicated a 
liver protective effect.  As the liver is the major organ for fatty acid synthesis and bile synthesis, 
lower level of LCA concentration may be one of the factors that lead to host body weight gain. 
 
The chicken growth performance data showed that from day 10 to 28, oral administration of 
BSH inhibitors to chickens did not cause statistical difference in body weight, even though 
chicken body weight from the BSH inhibitor groups had consistently higher body weight than in 
the control group.  A similar trend of advantages of chickens from BSH inhibitor treatment 
groups had superior feed conversion ratio than chickens from control group from day 10 to day 
24, the difference was only statistically significant during day 10 to14 of the treatment period.  
Power analysis showed that the power for chicken body weight data for each data point was 
higher than 0.8 which suggested that chicken body weight data had enough statistic power and 
low type II errors.  However, power analysis for chicken feed conversion data ranged from 0.076 
to 0.706.  To decrease type II error of the experiment, a larger animal trial (250 birds per 
treatment group) is needed to maintain a statistical power more than 0.8 for the BSH inhibitors 
effects validation.  
 
130 
  
The two most commonly used bioconductor packages, edgeR and Deseq2, were used for DEGs 
analysis in this study.  Both methods were used when count data had a negative binomial 
distribution (Anders et al., 2010; Kvam et al., 2012; Love et al., 2014; Robinson et al., 2010).  
These two methods normally give a higher power estimation, especially when the number of 
samples is less than five.  They provide the highest sensitivity of the algorithms that controll 
type-I error in the sense that actual False discovery rate (FDR) is below or at 0.1 (Ching et al., 
2014; Love et al., 2014).  However, with the same gene counts data, the revealed number of 
DEGs were different with the two different methods but the results have been inconsistent 
regarding which method is a better approach (Ching et al., 2014; Rajkumar et al., 2015).  The 
edgeR moderates the variance estimate for each gene toward a common estimate across all genes 
using a weighted conditional likelihood.  The DESeq2 approach corrects variance that is too low 
through modeling of the dependence of the variance on the average expression strength over all 
samples (Ching et al., 2014; Love et al., 2014).  In future studies, DEGs lists from both method 
can be compared to generate a new DEGs list which contains the genes from both methods for 
qRT-PCR validation, functional annotation, and canonical pathway analyses. 
 
To understand how BSH inhibitors impact host metabolic processes, we used RNA-Seq analysis 
of chicken liver and ileum tissues from the carnosic acid and control groups and identified 
several interesting genes.  The expression of the AKR1D1 gene in the liver was up-regulated by 
in carnosic acid treated chickens.  AKR1D1 belongs to the aldo-keto reductase family and it 
involves in significant steps in bile acid synthesis.  Multiple reactions happen from 7-α-
hydroxycholesterol to primary bile acids (cholic acid and chenodeoxycholic acid), and AKR1D1 
takes part in two different reduction steps in this process (Russell, 2003).  This is consistent with 
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the bile profile change in chicken fecal samples, where the concentration of cholic acid in the 
carnosic acid treatment group increased 17% compared to the control group; however, the serum 
concentration of cholic ancid and chenodeoxycholic acid between treatment group and control 
group were not statistically different. 
 
The CYP3A80 gene in chicken liver samples was also up-regulated by oral administration of 
carnosic acid.  DAVID-BR analysis revealed that CYP3A80 is related to secondary metabolites 
biosynthesis.  The CYP3A80 is predominantly expressed in the liver (Watanabe et al., 2013).  In 
chicken, CYP3A37 and CYP3A80 are presented in birds as CYP3A family genes (Watanabe et 
al., 2013).  Chicken CYP3A37 and CYP3A80 are 51% and 59% identical to human CYP3A4 
(Shang et al., 2013).  Even though the literature about CYP3A80 function is limited, the function 
of CYP3A4 is well understood.  CYP3A4 catalyzes the 6-hydroxylation of LCA, which is 
consistent with our funding that LCA in the chicken fecal samples from the carnosic acid 
treatment group is much lower than the samples from treatment group (Araya et al., 1999; 
Staudinger et al., 2001). 
 
The G0S2 gene was also up-regulated in the ileum samples from the chicken oral administrated 
with carnosic acid compared to the chicken from the control group.  The G0S2 gene is a highly 
conserved in vertebrates and it is a master regulator of tissue-specific balance of triglyceride 
storage and mobilization, partitioning of metabolic fuels between the adipose tissue, the liver and 
the whole body adaptive energy response (Zhang et al., 2017b).  G0S2 is a lipolysis inhibitor by 
inhibiting adipose triglyceride lipase (ATGL) which is responsible for catalyzing the first step of 
three step-wise reactions that define lipolysis (Zhang et al., 2017b; Zimmermann et al., 2004). 
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Multiple physiological roles of BSH inhibitors may confound the specifically desired feature of 
BSH inhibition, which was also verified by RNA-Seq analysis.  For example, carnosic acid is an 
anti-oxidant molecule and possesses anti-inflammatory and anti-carcinogenic properties 
(Aruoma et al., 1992; de Oliveira, 2016; Erkan et al., 2008).  This is verified by a list of DEGs 
related to immune and inflammation response in both liver and ileum tissues (Table 4-8).  
Carnosic acid exerts its anti-oxidant effects by the activation of the PI3K/Akt/Nrf2 signaling 
pathway, which would lead to the expression of anti-oxidant enzymes and neuronal 
differentiation (de Oliveira, 2016).  The activation of Nrf2 can induce the Nrf2-targeted genes 
such as GSTA3, which is confirmed by RNA-Seq analysis and qRT-PCR (Zhang et al., 2017a; 
Zhao et al., 2007).  In mouse a study, GST3 levels increased dramatically during adipose 
conversion process and the expression of GSTA3 is associated with acquisition of the adipocyte 
phenotype (Jowsey et al., 2003).  This may also contribute to the increased body weight (not 
statistically significant) of the broiler chickens receiving oral administration of carnosic acid. 
 
Due to the global trend of removing AGPs from food producing animals, alternatives to AGPs 
are urgently needed.  When developing effective non-antibiotic feed additives, development of 
effective and practical delivery approach is also highly warranted (Bento et al., 2013; 
Kailasapathy, 2009; Zhang et al., 2014b).  Leading encapsulation methods, such as 
microparticles and nanoparticles approaches, have shed light on improving the bioactivity and 
bioavailability of feed additives (Bale et al., 2016; Gangadoo et al., 2016).  In a recent study by 
Zhang et.al (Zhang et al., 2014b), the encapsulation of an essential oil carvacrol with alginate-
whey protein into dry microparticles showed high encapsulation efficiency.  Notably, the in vivo 
experiment also showed that carvacrol in microparticle form had good gastric resistance and 
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rapid intestinal release compared to unencapsulated carvarol during oral administration to 
chicken (Zhang et al., 2014b).  In another study, citral was proposed to control necrotic enteritis 
caused by Clostridium perfringens; oral administration of encapsulated citral showed a superior 
effect in reducing intestinal necrotic enteritis in broiler chickens compared to unencapsulated 
citral (Yang et al., 2016).  Besides, nanoparticles also enables feed additives to target organs or 
systems while avoiding fast degradation when passing through the GI tract, which would be 
promising to apply in our future study of BSH inhibitors in vivo effects, due to the fact that BSH 
inhibitors exert inhibition effects on bacterial BSHs in the host intestine (Gangadoo et al., 2016).  
The three compounds used in this study have characteristics that may weaken their bioactivity 
and bioavailability.  Riboflavin is a yellow powder which has good solubility in water.  
However, the rate of riboflavin destruction increases dramatically in oxygen permeable container 
during storage which is a challenge for riboflavin storage either separately or after mixing with 
food (Dennison et al., 1977).  The carnosic acid and CAPE have low water solubility, which is a 
challenge for delivery efficiency.  Therefore, to incorporate advanced encapsulation technology 
into BSH inhibitor-based non-antibiotic feed additive development is a promising approach for 
future study. 
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Table 4- 1. Primers for qRT-PCR used in this study. 
Genes Primer Sequence (5`-3`) Length 
(bp) 
Annealing 
Temperature 
(°C) 
Gene bank 
accession no. 
Liver     
AKR1D1 F: TCCACCAGAGCTGGTACGTC 319 53 NM_00127739
3.1  R: 
ATAGGGATGGCATTCAACCTGG 
CYP3A80 F: AATGGGACTCCTTCCAGACCT 235 53 NM_00132950
8.1  R: CCTGCCATCATAAATCCCCC 
GSTA3 F: AATTTCCCCTCTTGCAGAGTT 194 51 NM_00100177
7.1  R: CACTCCGCTTATCAGCAAAC 
Ileum     
G0S2 F: CGGCCTCAGAACGGAGC 113 54 NM_00119092
4.3  R: TCACCATCTTCCTGTTGGGC 
GSTA3 F: AATTTCCCCTCTTGCAGAGTT 194 51 NM_00100177
7.1  R: CACTCCGCTTATCAGCAAAC 
Internal 
reference 
    
β-actin F: CTCTGACTGACCGCGTTACT 172 53 NM_205518.1 
 R: TACCAACCATCACACCCTGAT 
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Table 4- 2. Body weight, feed conversion ratio and body weight gain in chickens treated 
with different BSH inhibitors. 
Chicken Body Weight (g/bird) 
Chicken 
Age 
Control CAPE Riboflavin Carnosic 
Acid 
MSE P value 
Day 7 163.56  162.57  164.19  162.76  3.79 0.99 
Day 10 249.42  244.91 258.46  251.58  5.55 0.43 
Day 14 421.16  421.37  431.98  436.48  8.73 0.54 
Day 17 580.32  585.68  611.68  601.10  13.61 0.40 
Day 21 813.11  829.46  869.59  859.72  20.39 0.25 
Day 24 967.95  1022.36  1053.10  1053.98  28.20 0.19 
Day 28 1234.26  1294.11  1304.03  1293.40  36.93 0.56 
Feed Conversion Ratio (g of feed/ g of weight gain) 
Chicken 
Age 
Control CAPE Riboflavin Carnosic 
Acid 
MSE P value 
Day 10-14 1.64 ab 1.56 b 1.81 a 1.53b 0.06 0.03 
Day 14-17 2.03  1.94  1.92  1.91  0.10 0.84 
Day 17-21 1.93  1.82  1.83  1.66  0.08 0.21 
Day 21-24 2.49  1.98  2.15  1.93  0.19 0.22 
Day 24-28 2.21  2.15  2.36  2.31  0.18 0.84 
Chicken Body Weight Gain (g/bird/day) 
Chicken 
Age 
Control CAPE Riboflavin Carnosic 
Acid 
MSE P value 
Day 7-10 28.68  27.45  31.48  29.58  1.02 0.11 
Day 10-14 42.99  44.15  43.33  46.11  1.47 0.48 
Day 14-17 53.05  54.77  59.90  54.87  2.67 0.36 
Day 17-21 58.20 60.95  64.48  64.66  2.33 0.23 
Day 21-24 51.61  64.30  61.17  64.75  4.23 0.18 
Day 24-28 66.67  68.06  62.78  59.90  4.12 0.52 
 
Growth performance data (body weight, body weight gain, and feed conversion ratio) is 
represented as least square means and mean square error [MSE].  Different letters in the same 
row represent significant difference between treatments (Tukey, P < 0.05). 
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Table 4- 3. Summary of chicken serum biochemical analyses in response to three different 
BSH inhibitors. 
Biochemical 
Parameters 
Control CAPE Riboflavin Carnosic 
Acid 
MSE P value 
Glucose (mg/dL) 224.49 189.96 186.32 186.58 9.77 0.08 
Total Cholesterol 
(mg/dL) 
96.94 91.84 105.26 110.61 7.94 0.33 
Triglycerides 
(mg/dL) 
42.69 40.20 39.35 41.86 3.95 0.85 
VLDL (mmol/L) 11.53 14.35 16.43 14.38 3.56 0.18 
 
Serum glucose, triglycerides and total cholesterol concentrations were expressed as least square 
means and mean square error [MSE].  Statistical significant level of difference is defined by 
P<0.05. 
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Table 4- 4. Bile salts profile alteration in chicken fecal samples (ng/g) in response to BSH 
inhibitors treatment. 
Bile Salts Control CAPE Riboflavin Carnosic 
Acid 
MSE P value 
Primary BA 105159  90700  108314  102713  31492 0.98 
All primary BA 106935  93581  111070  106105  31822 0.98 
Secondary/Tertiary 
BA 660.55
 a 391.94 ab 277.63 b 377.54 ab 72.11 0.03 
Unconjugated BA 107596  93974  111347  106484  31867 0.98 
Tauroconjugated 
BA 585103
  462953  831280  741745  152232 0.38 
Glycoconjugated 
BA 1911.53 1219.22
  2566.67  2375.07  566.92 0.40 
Total conjugated 
BA 586952
  464147  833837  744145  152534 0.38 
Total BA 695328  560087  945207  851290  166556 0.42 
Taurine 32157  21386  17501  19894  5627.11 0.33 
Cholic Acid 18346  20973  20952  21497  6857.69 0.99 
Chenodeoxycholic 
Acid 86840
  69913  87528  81231  25860 0.96 
Hyocholic Acid 128.7  207.72 157.03  284.59  60.1217 0.34 
Hyodeoxycholic 
Acid 30
  20.21  23.17  28.48  4.9952 0.51 
Murocholic Acid 31.6172 a 14.5006
 
ab 10.5949
 b 15.451 ab 4.3342 0.04 
a,w-Muricholic 
Acid 1250.77
  2035.6  1919.35 2408.9  621.05 0.63 
β-Muricholic Acid 233.53  437.71  631.33  612.78  162.04 0.33 
Ursodeoxycholic 
Acid 111.03
  80.5341  81.276  77.1654  18.5616 0.56 
Deoxycholic Acid 92.7548  106.04  68.409  79.3409  39.1108 0.91 
Lithocholic Acid 457.21 a 204.1 b 128.11 b 219.31 b 43.32 0.01 
Taurocholic Acid 176790  188016  337641  298439  73680 0.38 
Taurohyocholic 
Acid 906.6
  914.5  1648.41  1843.62 339.57 0.18 
Taurochenodeoxyc
holic Acid 393385 261451 462722
  420166  89789 0.47 
Tauroursodeoxycho
lic Acid 904.21
  622.09  1348.56  1038.45  235.52 0.26 
Taurodeoxycholic 
Acid 231.21
  158.14  301.33  411.91  88.07 0.29 
Taurohyodeoxychol
ic Acid 1301.23
  1328.43  3334.59  1679.47  574.52 0.11 
Taurolithocholic 
Acid 135.51
  87.88  215.82  174.94  41.12 0.23 
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Table 4- 4. Continued. 
Bile Salts Control CAPE Riboflavin Carnosic 
Acid 
MSE P value 
Tauromucholic 
Acid 11616
  10153  24077  18021  4311.96 0.17 
Glycocholic Acid 885.30 586.53  1652.44 1289.44 446.58 0.41 
Glycohyocholic 
Acid 61.18
  47.97  41.31  48.24  7.01 0.31 
Glycohyodeoxycho
lic Acid 125.34
 a 80.67 ab 55.42 b 95.13 ab 12.70 0.03 
Glycochenodeoxyc
holic Acid 572.46
  327.53  691.44  749.93  150.20 0.28 
Glycoursodeoxycho
lic Acid 127.72
 a 88.46 ab 73.82 b 92.14 ab 11.81 0.06 
Glycodeoxycholic 
Acid 126.12
 a 79.70 ab 46.33 b 87.48 ab 14.63 0.03 
Glycolithocholic 
Acid 14.24
  9.27  6.28  10.49  2.28 0.18 
 
Bile salt concentration was expressed as least square means and mean square error [MSE].  
Different letters in the same row represent significant difference between treatments (Tukey, P < 
0.05).   
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Table 4- 5. Bile salts profile alteration in chicken serum samples (ng/mL) in response to 
BSH inhibitors treatment. 
Bile Salts Control CAPE Riboflavin Carnosic 
Acid 
MSE P 
value 
Primary BA 367.62  394.89  648.51  369.17  168.15 0.61 
All primary BA 412.36  431.83  709.90  411.81  180.94 0.61 
Secondary/Tertiary BA 106.74  113.13  125.12  109.60  18.43 0.90 
Unconjugated BA 517.72  547.06  832.49  521.62  174.82 0.55 
Tauroconjugated BA 13249  11837  13689  13870  1911.94 0.87 
Glycoconjugated BA 168.08 159.61 158.6  163.52 15.29 0.97 
Total conjugated BA 13413  11997  13847 14032  1915.15 0.87 
Total BA 13931  12538  14684  14560  2031.31 0.87 
Taurine 5158.07 6303.62 5128.02 5486.30 462.94 0.32 
Cholic Acid 48.88  44.37  137.26  43.90  48.88 0.41 
Chenodeoxycholic 
Acid 319.07
  349.76  510.66  325.09  129.01 0.70 
Hyocholic Acid 7.83  7.19  7.14  6.90  1.61 0.98 
Hyodeoxycholic Acid 5.61  4.85  3.60  5.10  1.64 0.85 
Murocholic Acid 5.92  3.83  6.34  6.24  1.13 0.41 
a,w-Muricholic Acid 19.57  16.75  39.17  18.05 13.60 0.63 
β-Muricholic Acid 6.04  4.09  5.35  6.35  2.02 0.86 
Ursodeoxycholic Acid 22.89  18.30  16.19  22.72  5.62 0.80 
Deoxycholic Acid 26.88  24.97  42.06  25.80  12.88 0.76 
Lithocholic Acid 57.50  68.99  67.81  60.74  6.01 0.51 
Taurocholic Acid 1800.90 1716.03 2416.99 2202.29 445.02 0.66 
Taurohyocholic Acid 16.40  16.24  20.23 21.94  4.37 0.75 
Taurochenodeoxycholi
c Acid 11004
  9670.62 10664 11251  1500.11 0.89 
Tauroursodeoxycholic 
Acid 31.08
  33.62  34.76  31.56  4.41 0.93 
Taurodeoxycholic Acid 13.79  14.01  12.97  19.31  2.62 0.37 
Taurohyodeoxycholic 
Acid 70.37
  76.08  80.75  56.70  12.36 0.57 
Taurolithocholic Acid 15.25  18.07  25.14  21.44  3.68 0.34 
Tauromucholic Acid 296.93  304.84  450.66 261.07 114.68 0.67 
Glycocholic Acid 20.20  19.38  26.76  20.39  5.55 0.77 
Glycohyocholic Acid 16.23 a 11.65 ab 9.64 b 15.04 a 1.14 0.01 
Glycohyodeoxycholic 
Acid 26.03
  25.21  24.55  24.98  3.64 0.99 
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Table 4- 5. Continued.  
Bile Salts Control CAPE Riboflavin Carnosic 
Acid 
MSE P 
value 
Glycochenodeoxycholi
c Acid 50.13
  47.62  51  52.44  4.29 0.88 
Glycoursodeoxycholic 
Acid 22.99
  20.57  18.60 21.99  2.03 0.50 
Glycodeoxycholic Acid 28.11  31.74  24.48  25.09  3.41 0.46 
Glycolithocholic Acid 4.14  3.19  2.84  3.29  1.04 0.85 
 
Bile salt concentration was expressed as least square means and mean square error [MSE].  
Different letters in the same row represent significant difference between treatments (Tukey, P < 
0.05).
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Table 4- 6. RNA Sample description and mapping statistics to reference genome. 
 
a T stands for treatment; C stands for control.  
 
Tag 
name 
Treat
ment a 
Concentra
tion 
(ng/µL) 
RIN 28S/18S Number of 
reads in pair 
(raw) 
Number of 
reads in pair 
(Q trimmed) 
Mapping 
Rate (%) 
Non-specific 
mapping of 
mapped (%) 
Liver         
LT1 T 320 8.6 1.9 26343666 24990680 86.4 3.4 
LT2 T 2664 9.4 2.1 37647864 35569752 86.7 3.6 
LT3 T 4328 9.2 1.9 9188235 8510958 85.0 3.3 
LT4 T 848 9.2 1.9 90545141 84666914 68.9 3.4 
LC1 C 3576 9.2 2.1 27499176 25823234 88.2 3.5 
LC2 C 3216 9.1 2.0 14620336 13514440 86.4 3.5 
LC3 C 4760 9.1 2.1 36029297 34089068 85.8 4.1 
LC4 C 4912 9.3 2.2 134362985 128352800 64.8 3.8 
Ileum         
IT1 T 2088 9.5 2.0 14406611 13461675 82.8 4.18 
IT2 T 3424 9.6 2.2 14867215 14004769 83.4 4.0 
IT3 T 2320 9.4 2.0 20300211 18961626 84.1 4.3 
IT4 T 1460 8.9 2.0 29154179 27535357 82.6 5.5 
IC1 C 2068 9.0 1.8 18346963 17380507 83.7 7.9 
IC2 C 1524 9.3 1.9 162762428 155661706   61.2 4.0 
IC3 C  1476 8.6 1.8 35944368 33371893 82.8 4.6 
IC4 C 320 8.9 1.8 13162436 12258294 82.2 4.0 
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Table 4- 7. The number of differentially expressed genes detected by three different 
methods. 
Tissue DEGs method Number of up 
regulated gene 
Number of 
down regulated 
gene 
Total number 
of DEGs 
Liver edgeR 495 112 607 
 DeSeq_1 360 248 608 
 DeSeq_2 617 296 913 
Ileum edgeR 116 99 215 
 DeSeq_1 246 230 476 
 DeSeq_2 289 234 523 
 
DeSeq_1 means analysis conducted under R environment with DeSeq package, in the statistic 
model animal tissue and treatment were fixed effects and individual animal were used as 
repeated measure; DeSeq_2 means analysis conducted under R environment with DeSeq 
package, in the statistic model individual animal, animal tissue and treatment were fixed effects. 
edgeR means analysis conducted under R environment with DeSeq package, in the statistic 
model animal tissue and treatment were fixed effects and individual animal were used as 
repeated measure. 
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Table 4- 8. Representative differentially expressed genes in response to carnosic acid 
treatment based on DAVID bioinformatics resourcesa. 
Tissue Gene name Potential 
function 
References 
Liver    
Up 
regulated 
CD3e molecule(CD3E) Immune 
 
(Ueda et al., 
2017) 
 2'-5'-oligoadenylate synthetase-
like(OASL) 
 
 Major histocompatibility 
complex class II beta chain 
BLB1(BLB1) 
(Wang et al., 
2012a) 
 aldo-keto reductase family 1, 
member D1 (delta 4-3-
ketosteroid-5-beta-
reductase)(AKR1D1) 
Bile acid 
metabolism 
(Russell, 2003) 
 phosphoglycerate 
dehydrogenase(PHGDH) 
Taurine 
metabolism 
(Xie et al., 
2016) 
 apolipoprotein D(APOD) Lipid metabolism (Perdomo et al., 
2009) 
 lipase, member I(LIPI)  
 adenylate kinase 1(AK1) Energy 
metabolism 
(Janssen et al., 
2003) 
 protein kinase, AMP-activated, 
gamma 3 non-catalytic 
subunit(PRKAG3) 
Glucose 
metabolism 
 
 cytochrome P450, family 2, 
subfamily C, polypeptide 
23a(CYP2C23a) 
Secondary 
metabolites 
biosynthesis  
 
 cytochrome P450, family 3, 
subfamily A, polypeptide 
80(CYP3A80) 
(Staudinger et 
al., 2001) 
 cytochrome P450, family 4, 
subfamily B, polypeptide 
7(CYP4B7) 
 
 
 glutamine synthetase-
like(LOC417253) 
Carnosic acid 
metabolism 
related 
(Tong et al., 
2017; Zhang et 
al., 2017a)  glutathione S-transferase alpha 
3(GSTA3) 
 glutathione S-transferase omega 
1(GSTO1) 
 glutathione S-transferase-
like(LOC100859645) 
171 
  
Table 4- 8. Continued. 
Tissue Gene name Potential 
function 
References 
Liver insulin like growth factor 
binding protein 5(IGFBP5) 
Insulin regulation  
Down 
regulated 
S100 calcium binding protein 
A9(S100A9) 
Immune 
 
 
 T-cell immunoglobulin and 
mucin domain containing 
4(TIMD4) 
 
 
avian beta-defensin 1(AvBD1) 
(Cuperus et al., 
2013) 
 avian beta-defensin 2(AvBD2)  
 avian beta-defensin 6(AvBD6)  
 
cathelicidin-1(CATH1) 
(Cuperus et al., 
2013) 
 cathelicidin-2(CATH2)  
 cytochrome P450 family 39 
subfamily A member 
1(CYP39A1) 
Bile acid 
metabolism and 
liver health 
(Khenjanta et 
al., 2014; 
Russell, 2003) 
 mitogen-activated protein 
kinase kinase kinase 
15(MAP3K15) 
(Noel et al., 
2016) 
 hexokinase domain containing 
1(HKDC1) 
Carbohydrate 
metabolism 
 
 solute carrier family 7 (amino 
acid transporter light chain, L 
system), member 5(SLC7A5) 
Amino 
metabolism  
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Table 4- 8. Continued. 
Tissue Gene name Potential 
function 
References 
Ileum    
Up 
regulated 
2'-5'-oligoadenylate synthetase-
like(OASL) 
Immune   
 eomesodermin(EOMES) (Šahmatova et 
al., 2017) 
 radical S-adenosyl methionine 
domain containing 2(RSAD2) 
(De Wit et al., 
2008) 
 ATP-binding cassette, sub-
family C (CFTR/MRP), 
member 2(ABCC2) 
Carnosic  acid 
metabolism 
related 
(Yan et al., 
2015) 
 aldehyde dehydrogenase 8 
family member A1(ALDH8A1) 
(Wu et al., 
2012) 
 glutathione S-transferase alpha 
3(GSTA3) 
 
 prostaglandin reductase 
1(PTGR1) 
(Wu et al., 
2011) 
 G0/G1 switch 2(G0S2) Lipolysis and 
energy harvest 
(Kitareewan et 
al., 2008; Zhang 
et al., 2017b) 
 hydroxyacid oxidase (glycolate 
oxidase) 1(HAO1) 
Fatty acid alpha-
oxidation  
 
 solute carrier family 2 
(facilitated glucose/fructose 
transporter), member 
5(SLC2A5) 
Fructose 
absorption 
(Barone et al., 
2009) 
 aldehyde dehydrogenase 8 
family member A1(ALDH8A1) 
  
 cytochrome P450, family 2, 
subfamily C, polypeptide 
23a(CYP2C23a) 
Secondary 
metabolites 
biosynthesis 
 
 glucagon receptor(GCGR) Bile acid 
metabolism 
(Ikegami et al., 
2006) 
 eomesodermin(EOMES)   
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Table 4- 8. Continued. 
Tissue Gene name Potential 
function 
References 
Ileum    
Down 
regulated 
ATP-binding cassette, sub-
family G (WHITE), member 
1(ABCG1) 
Lipid metabolism (Schmitz et al., 
2001) 
 
alkaline ceramidase 2(ACER2) 
Lipid metabolism  (Jiang et al., 
2015) 
 C-C motif chemokine receptor 
10(CCR10) 
Immune and 
inflammation 
(Homey et al., 
2002) 
 CD247 molecule(CD247)   
 transcription factor 7 (T-cell 
specific, HMG-box)(TCF7) 
  
 
NADPH oxidase 1(NOX1) 
Carnosic acid 
metabolism 
related 
(Buendia et al., 
2016) 
 NADPH oxidase organizer 
1(NOXO1) 
  
 family with sequence similarity 
132 member A(FAM132A) 
Insulin regulation   
 hydroxyacid oxidase 2 (long 
chain)(HAO2) 
Fatty acid 
oxidation 
 
 putative short-chain 
dehydrogenase/reductase family 
42E member 2-
like(LOC771638) 
Steroid 
biosynthesis 
 
 
a Determined by DAVID bioinformatics resources (https://david.ncifcrf.gov/). 
The genes denoted as up-regulated indicated that those genes have higher expression in 
carnosic acid treatment group than in the control group; genes denoted as down-regulated 
indicated that those genes have lower expression in carnosic acid treatment group than in 
the control group. All genes showing a significant difference in expression had the cut-off 
of P-value ≤0.05.  
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Table 4- 9. Comparison of RNA-Seq and qPCR analyses of the selected genes 
involved in bile acid metabolism and lipid metabolism in response to oral 
administration of carnosic acid in broilers. 
Tissue Gene RNA-Seq qPCR 
  Log2 fold 
-change 
fold-
change 
P value Log2 fold 
-change 
fold-
change 
P 
value 
Liver AKR1D1 -1.43 2.69 0.02 -1.59 3.02 0.43 
 CYP3A80 -0.81 1.75 0.05 -0.73 1.66 0.06 
 GSTA3 -1.95 3.85 <0.001 -1.13 2.19 0.28 
Ileum G0S2 -2.04 4.12 0.02 -1.63 3.10 0.05 
 GSTA3 -1.29 2.44 0.03 -1.15 2.22 0.09 
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Figure 4- 1. The RNA-Seq pipeline and comparison of the software used for RNA-
Seq data analysis and software/packages at Rutgers University (collaborator) and 
The University of Tennessee, Knoxville.  
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Figure 4- 2. Representative bile acids profile in chicken fecal samples by UPLC-MS.  
(A) Concentration of taurine in chicken fecal samples from BSH inhibitors groups and 
treatment group.  (B) Concentration of conjugated bile salts in chicken fecal samples 
from BSH inhibitors groups and treatment group.  (C) Concentration of 
secondary/tertiary bile salts in chicken fecal samples from BSH inhibitors group and 
treatment group.  (D) Concentration of lithocholic acid in chicken fecal samples from 
BSH inhibitors groups and treatment group. 
  
177 
  
 
 
Figure 4- 3. Venn diagram of the number of differentially expressed genes detected 
by three different methods. DeSeq_1 means analysis conducted under R environment 
with DeSeq package, in the statistic model animal tissue and treatment were fixed effects 
and individual animal were used as repeated measure; DeSeq_2 means analysis 
conducted under R environment with DeSeq package, in the statistic model individual 
animal, animal tissue and treatment were fixed effects. edgeR means analysis conducted 
under R environment with DeSeq package, in the statistic model animal tissue and 
treatment were fixed effects and individual animal were used as repeated measure. (A) 
Comparison of number of DEGs up regulated in the liver with three methods. (B) 
Comparison of number of DEGs down regulated in the liver with three methods. (C) 
Comparison of number of DEGs up regulated in the ileum with three methods. (D) 
Comparison of number of DEGs down regulated in the ileum with three methods. 
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Conclusions and perspectives 
Bile salt hydrolase (BSH) catalyzes the essential gateway reaction for bile acid 
metabolism by deconjugates the conjugated bile salts into unconjugated bile salts and 
taurine or glycine (Begley et al., 2006).  Bile salts plays dual role in host lipid absorption 
and signaling via some key signaling molecules such as FXR and TGR5, thus exerts 
effects on host lipid metabolism and energy harvest (Joyce et al., 2014b).  Animal studies 
also provided direct and indirect evidence of BSH function on host lipid metabolism and 
energy harvest (Begley et al., 2006; Joyce et al., 2014a; Lin, 2014).  These evidence 
make BSH as a promising target of developing alternatives for antibiotic growth 
promoters and as new measures for control obesity.  However, research on BSH is still in 
its infancy regarding to its basic science and translation innovation. 
 
Our preliminary rat study showed that oral administration of Zucker fatty rats with 
purified BSH enzyme significantly increased rat respiratory exchange ratio, suggesting 
reduction of host lipid digestion or absorption.  In the study presented in Chapter II, 
sufficient high quality BSH was purified and subsequently encapsulated for rat oral 
administration.  In rat study, solid direct evidence related to BSH function towards host 
lipid metabolism and energy harvest was not obtained, despite dramatic fecal bile profile 
change in response to BSH treatment.  In the future, direct evidence of in vivo BSH 
function is needed in different systems, such as using different an animal model or using 
a more efficient protein encapsulation system.  
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In a previous study, the crystal structure of Lactobacillus salivarius BSH (lsBSH) was 
revealed (Xu et al., 2016).  In Chapter III, based on structure comparison of lsBSH and 
previous published BSH structure from other bacteria resources, key amino acid residues 
of lsBSH for enzyme activity and substrate specificity were revealed.  These residues 
were verified by site-directed mutagenesis and mutants’ activity were tested by two step 
enzyme activity assay.  These structure analysis on lsBSH provided a solid foundation for 
BSH structural analysis.  Due to the significant role of BSH in host physiology, in the 
future, structural based BSH inhibitors (potential alternatives for AGPs) and BSH 
enhancers (potential lead drug to control obesity) need to be developed by molecule 
docking.  Those hits with outstanding enhancing or inhibiting effects on BSH could be 
further validated with in vivo and in vitro experiment. 
 
Due to BSH negative relation to host lipid metabolism, BSH inhibitors could be potential 
alternatives for AGPs (Lin, 2014).  A group of promising BSH inhibitors were 
characterized using an effective High-Throughput Screening (HTS) system (Smith et al., 
2014).  In chapter VI, three BSH inhibitors verified by HTS on host bile acid metabolism 
and lipid metabolism were validated in a chicken experiment.  Growth performance data 
did not showed significant difference among three BSH inhibitors group and control 
group.  Metabolomics analysis of intestinal samples using UPLC-MS showed some 
significant changes in bile acid profile in response to BSH inhibitors treatment suggesting 
in vivo efficacy of the BSH inhibitors.  Transcriptome analysis of liver and intestine 
samples indicated that carnosic acid treatment caused differential expression of genes 
involved in lipid metabolism, bile acid metabolism and host immunology.  Future larger 
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animal trial to validate the efficiency of BSH inhibitors on farm animal growth 
promotion.  Some leading encapsulation methods can also be used for developing 
effective and practical delivery approach to apply promising BSH inhibitors to food 
animal industry. 
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